[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1487
1. Stuff JE, Goh ET, Barrera SL, Bondy ML, Forman MR: Construction of an N-nitroso database for assessing dietary intake. J Food Compost Anal; 2009 Dec 1;22(Suppl 1):S42-S47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quantification of the dietary intake of N-nitroso compounds is significant to human cancers, including those of the stomach and upper gastro-intestinal tract, colon, and brain.
  • Previous studies investigating these cancers primarily used proxy estimates of N-nitroso intake and not a full and complete database.
  • Using the FFQ modified with N-nitroso values, we evaluated the ability to compute N-nitroso intakes for a sample of healthy control subjects of cancer epidemiological studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20161416.001).
  • [ISSN] 0889-1575
  • [Journal-full-title] Journal of food composition and analysis : an official publication of the United Nations University, International Network of Food Data Systems
  • [ISO-abbreviation] J Food Compost Anal
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103515-01; United States / NCI NIH HHS / CA / R01 CA070917; United States / NCI NIH HHS / CA / R03 CA103515
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


2. Xie Y, Chao M, Lee P, Xing L: Feature-based rectal contour propagation from planning CT to cone beam CT. Med Phys; 2008 Oct;35(10):4450-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proposed technique provides a powerful tool for adaptive radiotherapy of prostate, rectal, and gynecological cancers in the future.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comput Med Imaging Graph. 2003 Jul-Aug;27(4):267-81 [12631511.001]
  • [Cites] Med Phys. 2008 Mar;35(3):1145-53 [18404949.001]
  • [Cites] Med Phys. 2003 Oct;30(10):2750-7 [14596313.001]
  • [Cites] Phys Med Biol. 2004 Jul 21;49(14):3067-87 [15357182.001]
  • [Cites] Neuroimage. 1997 Jan;5(1):31-40 [9038282.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):195-206 [9873906.001]
  • [Cites] Med Phys. 2004 Nov;31(11):2942-8 [15587645.001]
  • [Cites] Med Phys. 2004 Nov;31(11):3087-94 [15587662.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Oct;27(10):1615-30 [16237996.001]
  • [Cites] Phys Med Biol. 2005 Dec 21;50(24):5869-92 [16333161.001]
  • [Cites] Phys Med Biol. 2006 Mar 7;51(5):1077-99 [16481679.001]
  • [Cites] Med Phys. 2006 Feb;33(2):446-54 [16532952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1537-50 [16503382.001]
  • [Cites] Med Dosim. 2006 Summer;31(2):91-112 [16690451.001]
  • [Cites] Med Phys. 2006 Apr;33(4):1165-79 [16696494.001]
  • [Cites] Phys Med Biol. 2006 Oct 7;51(19):4789-806 [16985271.001]
  • [Cites] Med Phys. 2006 Sep;33(9):3304-12 [17022225.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):522-30 [17418960.001]
  • [Cites] Phys Med Biol. 2007 Jul 21;52(14):4137-53 [17664599.001]
  • [Cites] Semin Radiat Oncol. 2007 Oct;17(4):245-57 [17903702.001]
  • [Cites] Med Phys. 2007 Nov;34(11):4098-108 [18072476.001]
  • [Cites] Math Biosci Eng. 2008 Jan;5(1):125-44 [18193935.001]
  • [Cites] Med Phys. 2003 Jun;30(6):1128-33 [12852537.001]
  • (PMID = 18975692.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098523; United States / NCI NIH HHS / CA / R01 CA104205; United States / NCI NIH HHS / CA / 1R01 CA98523; United States / NCI NIH HHS / CA / CA104205
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2736756
  •  go-up   go-down


3. Pocard M, Sabourin JC: [Not Available]. J Chir (Paris); 2008 Dec;145S4:12S17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le ganglion sentinelle en pathologie digestive : données actuelles et implications à venir.
  • Sabourin In theory, the concept of sentinel lymph node (SLN) biopsy can be applied to cancer surgery for all solid cancers.
  • Yet sentinel lymph node biopsy has not become a standard part of gastrointestinal cancer surgery.
  • It has been of value in the assessment of small early-stage gastric cancers, but has only achieved widespread practice in Japan.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22793980.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr Opin HIV AIDS; 2010 Nov;5(6):531-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biomarkers in HIV patients.
  • PURPOSE OF REVIEW: In this review, we update investigations related to cancer biomarkers in HIV-infected populations.
  • RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system lymphoma (PCNSL), systemic non-Hodgkin's lymphoma (NHL) (except perhaps for Burkitt lymphoma), Kaposi's sarcoma, cervical cancer, and anal cancer.
  • HIV load is associated with Burkitt lymphoma and systemic NHL (but not PCNSL), with Kaposi's sarcoma and with anal cancer.
  • B-cell activation as manifest in immunoglobulin light chain production may be an important marker for NHL risk.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1396-7; author reply 1397-8 [15494920.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):760-4 [15721423.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]
  • [Cites] J Clin Virol. 2008 Aug;42(4):433-6 [18455472.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9 [19322036.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2496-502 [19349542.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2354; author reply 2354-5 [19745076.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2730-2 [19638620.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22 [19770804.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91 [19835968.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):497-506 [20038229.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1514-9 [20177022.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]
  • [Cites] Cancer Causes Control. 2010 May;21(5):759-69 [20087644.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] J Natl Cancer Inst. 2010 Jun 2;102(11):784-92 [20442214.001]
  • [Cites] BMC Cancer. 2010;10:278 [20537184.001]
  • [Cites] Clin Infect Dis. 2010 Aug 1;51(3):342-9 [20572760.001]
  • [Cites] PLoS One. 2010;5(7):e11448 [20625427.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 20978397.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947-05; United States / NCI NIH HHS / CA / CA096888-05S2; United States / NCI NIH HHS / CA / UO1 CA 121947; United States / NCI NIH HHS / CA / P50 CA096888-05S2; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS274983; NLM/ PMC3055562
  •  go-up   go-down


5. Schöllnberger H, Stewart RD, Mitchel RE: Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model. Dose Response; 2005;3(4):508-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model.
  • A stochastic two-stage cancer model with clonal expansion was used to investigate the potential impact on human lung cancer incidence of some aspects of the hormesis mechanisms suggested by Feinendegen (Health Phys.
  • Non-linear responses arise in the model because radiologically induced adaptations in radical scavenging and DNA repair may reduce the biological consequences of DNA damage formed by endogenous processes and ionizing radiation.
  • Sensitivity studies were conducted to identify critical model inputs and to help define the changes in cellular defense mechanisms necessary to produce a lifetime probability for lung cancer that deviates from a linear no-threshold (LNT) type of response.
  • Our studies suggest that lung cancer risk predictions may be very sensitive to the induction of DNA damage by endogenous processes.
  • For doses comparable to background radiation levels, endogenous DNA damage may account for as much as 50 to 80% of the predicted lung cancers.
  • For an additional lifetime dose of 1 Gy from low-LET radiation, endogenous processes may still account for as much as 20% of the predicted cancers (Fig. 2).
  • When both repair and scavengers are considered as inducible, radiation must enhance DNA repair and radical scavenging in excess of 30 to 40% of the baseline values to produce lifetime probabilities for lung cancer outside the range expected for endogenous processes and background radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):674-9 [11237389.001]
  • [Cites] Radiat Res. 2002 Aug;158(2):181-6 [12105988.001]
  • [Cites] Int J Radiat Biol. 2000 Oct;76(10):1365-75 [11057745.001]
  • [Cites] Radiat Res. 2000 Aug;154(2):178-86 [10931690.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):73-116 [10686307.001]
  • [Cites] Mutat Res. 1999 Sep 13;435(1):43-61 [10526216.001]
  • [Cites] Int J Radiat Biol. 1999 Sep;75(9):1189-99 [10528927.001]
  • [Cites] Radiat Res. 1999 Sep;152(3):273-9 [10453088.001]
  • [Cites] Radiat Environ Biophys. 1999 May;38(1):57-71 [10384956.001]
  • [Cites] Science. 1998 May 15;280(5366):1066-9 [9582118.001]
  • [Cites] Radiat Res. 1998 May;149(5):517-20 [9588363.001]
  • [Cites] Radiat Environ Biophys. 1997 Jun;36(2):85-8 [9271795.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Radiat Environ Biophys. 1997 Feb;36(1):45-58 [9128898.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Radiat Res. 1996 Nov;146(5):582-5 [8896586.001]
  • [Cites] Radiat Res. 1996 Oct;146(4):369-73 [8927708.001]
  • [Cites] Mutat Res. 1996 Sep 23;356(2):209-16 [8841487.001]
  • [Cites] Histol Histopathol. 1996 Jan;11(1):237-55 [8720467.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1278-91 [8589222.001]
  • [Cites] Risk Anal. 1994 Dec;14(6):1079-80 [7846315.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] Risk Anal. 1993 Jun;13(3):273-9 [8341806.001]
  • [Cites] Free Radic Biol Med. 1991;11(3):299-306 [1937147.001]
  • [Cites] N Engl J Med. 1989 Nov 9;321(19):1285-9 [2797101.001]
  • [Cites] Risk Anal. 1990 Jun;10(2):323-41 [2195604.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6 [14610281.001]
  • [Cites] Int J Radiat Biol. 2003 Apr;79(4):235-40 [12775447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):767-74 [12618888.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):691-2 [12610596.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):433-6 [12600247.001]
  • [Cites] Ann ICRP. 2006;36(1-2):25-327, iii [17188183.001]
  • [Cites] Risk Anal. 2001 Feb;21(1):103-5 [11332539.001]
  • [Cites] Radiat Res. 2001 Dec;156(6):700-7 [11741493.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):320-7 [12600234.001]
  • [Cites] Int J Radiat Biol. 2002 Dec;78(12):1139-47 [12556341.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4115-39 [11205238.001]
  • (PMID = 18648628.001).
  • [ISSN] 1559-3258
  • [Journal-full-title] Dose-response : a publication of International Hormesis Society
  • [ISO-abbreviation] Dose Response
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2477198
  • [Keywords] NOTNLM ; LNT / endogenous damage / hormesis / low-LET / lung cancer / radioprotective mechanisms / threshold
  •  go-up   go-down


6. Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D: Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 2008 Dec;17(12):3467-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer.
  • Insulin-like growth factors (IGF) have been associated with risk of common human cancers, but the association between IGFs and pancreatic cancer risk is unclear.
  • To determine whether genetic variations of IGF modify pancreatic cancer risk, we compared the frequency of six single nucleotide polymorphisms of IGF1 and IGF2 in a large-scale case control study.
  • Anderson Cancer Center from 2000 to 2007.
  • A statistically significant joint effect of the IGF1 3'-UTR Ex4 -177 G>C C allele and diabetes on pancreatic cancer risk was observed.
  • The IGF2 3'-UTR Ex4 -233C>T TT genotype was significantly associated with a reduced risk of pancreatic cancer (OR = 0.07; 95% CI = 0.01-0.57; P = 0.013).
  • The polymorphic variants of the IGF genes may serve as a susceptibility factor for pancreatic cancer.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Mar 25;307(5717):1976-8 [15731405.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):144-51 [15668488.001]
  • [Cites] Urol Oncol. 2005 Jul-Aug;23(4):225-9 [16018936.001]
  • [Cites] Growth Horm IGF Res. 2005 Oct;15(5):360-2 [16102992.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):103-11 [15987714.001]
  • [Cites] Hum Mol Genet. 2006 Jan 1;15(1):1-10 [16306136.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 18;98(2):123-34 [16418515.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):299-307 [16404426.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 21;346(1):38-44 [16750516.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):98-104 [17533398.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2734-8 [17488802.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1667-74 [17684144.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2154-9 [17724372.001]
  • [Cites] Am J Gastroenterol. 2007 Dec;102(12):2696-707 [17764494.001]
  • [Cites] Am J Gastroenterol. 2008 Feb;103(2):360-7 [17986315.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):880-8 [18398029.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4928-35 [18544627.001]
  • [Cites] Cell Mol Life Sci. 2000 Jun;57(6):932-42 [10950308.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1124-30 [11355889.001]
  • [Cites] Hum Mol Genet. 2001 Jul 1;10(14):1491-501 [11448941.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):297-306 [11854392.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):298-302 [12067807.001]
  • [Cites] Int J Cancer. 2002 Jul 20;100(3):332-6 [12115549.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):19-26 [12125963.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4630-6 [12183419.001]
  • [Cites] Trends Biochem Sci. 2003 Feb;28(2):91-8 [12575997.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 28;302(1):46-55 [12593846.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1753-5 [12637750.001]
  • [Cites] Int J Exp Pathol. 2002 Oct;83(5):239-45 [12641820.001]
  • [Cites] Hum Mol Genet. 2003 Jul 1;12(13):1569-78 [12812984.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):438-44 [15006921.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Mol Cancer. 2003 Jan 6;2:4 [12556242.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):103-7 [2152769.001]
  • [Cites] Eur J Surg. 1993 Feb;159(2):101-7 [8098623.001]
  • [Cites] BMJ. 1995 Jan 21;310(6973):170 [7833759.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2007-11 [7743492.001]
  • [Cites] JAMA. 1995 May 24-31;273(20):1605-9 [7745774.001]
  • [Cites] Int J Obes Relat Metab Disord. 1997 Sep;21(9):822-5 [9376897.001]
  • [Cites] Int J Pancreatol. 1997 Oct;22(2):95-100 [9387030.001]
  • [Cites] Genet Anal. 1999 Feb;14(5-6):143-9 [10084106.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2076-83 [15886696.001]
  • (PMID = 19064563.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA98380; United States / NCI NIH HHS / CA / R01 CA098380-05; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / R01 CA098380-04; United States / NIEHS NIH HHS / ES / P30 ES07784; United States / NCI NIH HHS / CA / CA098380-05; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NCI NIH HHS / CA / CA098380-04; United States / NCI NIH HHS / CA / R01 CA098380
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ NIHMS70982; NLM/ PMC2600618
  •  go-up   go-down


7. Hong S, Lee D, Zhang H, Zhang JQ, Resvick JN, Khademhosseini A, King MR, Langer R, Karp JM: Covalent immobilization of p-selectin enhances cell rolling. Langmuir; 2007 Nov 20;23(24):12261-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Covalent immobilization of p-selectin enhances cell rolling.
  • Cell rolling is an important physiological and pathological process that is used to recruit specific cells in the bloodstream to a target tissue.
  • This process may be exploited for biomedical applications to capture and separate specific cell types.
  • One of the most commonly studied proteins that regulate cell rolling is P-selectin.
  • By coating surfaces with this protein, biofunctional surfaces that induce cell rolling can be prepared.
  • The prepared surfaces were first tested in a flow chamber by flowing microspheres functionalized with a cell surface carbohydrate (sialyl Lewis(x)) that binds to P-selectin.
  • Adhesion bonds between P-selectin and sialyl Lewis(x) dissociate readily under shear forces, leading to cell rolling.
  • This work is essential for the future development of devices for isolating specific cell types based on cell rolling, which may be useful for hematologic cancers and certain metastatic cancer cells that are responsive to immobilized selectins.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Jul 14;477(1-2):84-8 [10899315.001]
  • [Cites] Biophys J. 2000 Aug;79(2):694-706 [10920004.001]
  • [Cites] J Phys Chem B. 2005 Sep 22;109(37):17545-52 [16853244.001]
  • [Cites] Carbohydr Res. 2006 Jul 24;341(10):1209-34 [16716275.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):1942-7 [16131484.001]
  • [Cites] Biomed Microdevices. 2007 Apr;9(2):207-14 [17160704.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4812-20 [17172469.001]
  • [Cites] Drug Discov Today. 2006 Nov;11(21-22):1034-40 [17055414.001]
  • [Cites] Biotechnol Bioeng. 2001 Apr 20;73(2):111-24 [11255159.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):569-77 [11544025.001]
  • [Cites] Biophys J. 2001 Oct;81(4):2001-9 [11566773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14919-24 [11752440.001]
  • [Cites] Biophys J. 2002 Apr;82(4):1835-47 [11916843.001]
  • [Cites] J Cell Biol. 2002 Aug 19;158(4):787-99 [12177042.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):581-6 [12231353.001]
  • [Cites] Med Res Rev. 2002 Nov;22(6):566-601 [12369089.001]
  • [Cites] Curr Med Chem. 2004 Aug;11(16):2153-60 [15279555.001]
  • [Cites] Cell. 1991 May 31;65(5):859-73 [1710173.001]
  • [Cites] Cell. 1994 Jan 28;76(2):301-14 [7507411.001]
  • [Cites] Physiol Rev. 1999 Jan;79(1):181-213 [9922371.001]
  • [Cites] Lab Chip. 2005 Jan;5(1):64-73 [15616742.001]
  • [Cites] Biophys J. 2005 Mar;88(3):1676-83 [15574709.001]
  • [Cites] Math Biosci. 2005 Mar;194(1):71-9 [15836865.001]
  • [Cites] Annu Rev Biomed Eng. 2005;7:151-85 [16004569.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5453-9 [16131052.001]
  • (PMID = 17949112.001).
  • [ISSN] 0743-7463
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL060435-05; United States / NHLBI NIH HHS / HL / R01 HL060435; United States / NHLBI NIH HHS / HL / HL 060435; United States / NHLBI NIH HHS / HL / R01 HL060435-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Amines; 0 / Epoxy Compounds; 0 / Oligosaccharides; 0 / P-Selectin
  • [Other-IDs] NLM/ NIHMS62699; NLM/ PMC2546510
  •  go-up   go-down


8. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Radiation Injuries / etiology. Radiation Injuries / surgery. Radiotherapy Dosage. Risk Factors. Treatment Failure

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kondepati VR, Heise HM, Backhaus J: Recent applications of near-infrared spectroscopy in cancer diagnosis and therapy. Anal Bioanal Chem; 2008 Jan;390(1):125-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent applications of near-infrared spectroscopy in cancer diagnosis and therapy.
  • In recent years, near-infrared spectroscopy (NIRS) has gained importance for non-invasive or minimally invasive diagnostic applications in cancer.
  • This technology is based on differences of endogenous chromophores between cancer and normal tissues using either oxy-haemoglobin or deoxy-haemoglobin, lipid or water bands, or a combination of two or more of these as diagnostic markers.
  • These marker bands provide a basis for the diagnosis and therapy monitoring of several cancers.
  • It will provide an overview on the importance of the NIRS tools in cancer pathology, and in the near future it is envisaged to play a crucial role in cancer diagnosis, treatment decisions, and defining therapeutic drug levels.
  • [MeSH-major] Neoplasms / diagnosis. Neoplasms / therapy. Spectroscopy, Near-Infrared / instrumentation. Spectroscopy, Near-Infrared / methods
  • [MeSH-minor] Animals. Biomarkers, Tumor. Humans

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17955220.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 95
  •  go-up   go-down


10. Wang C, Zhou ZG, Yu YY, Yang L, Wang ZQ, Shu Y: Selective laparoscopic lateral dissection of regional micrometastasis in rectal carcinoma--ten years single center experience. Minim Invasive Ther Allied Technol; 2010 Dec;19(6):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective laparoscopic lateral dissection of regional micrometastasis in rectal carcinoma--ten years single center experience.
  • Although total mesorectal excision (TME) has been generally accepted as a principle of rectal cancer surgery, the corresponding laparoscopic approach still needs evaluation in depth, especially the controversial dissection of lateral pelvic areas.
  • At our center, 982 patients with rectal cancers received laparoscopic or laparoscopic-assisted surgery during the past ten years.
  • Short-term results showed an anastomic leakage rate of 4.2% (29/683) in patients with anal sphincter preservation and an average hospitalization of 8.8 days.
  • Sixty-two cases (6.3%) suffered postoperative urinary dysfunction while well-controlled defecation was observed in 87.6% cases that underwent colo-rectal/colo-anal anastomosis.
  • Lateral metastasis was more common in lower located cancers while laparoscopic lateral dissection is practical and safe when performed by trained surgeons.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Anastomotic Leak / epidemiology. Female. Hospitalization. Humans. Length of Stay. Male. Middle Aged. Neoplasm Metastasis. Postoperative Complications / epidemiology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091068.001).
  • [ISSN] 1365-2931
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. de Parades V, Etienney I, Bauer P, Bourguignon J, Meary N, Mory B, Sultan S, Taouk M, Thomas C, Atienza P: Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis--an effective but not risk-free procedure: a prospective study of 33 patients. Dis Colon Rectum; 2005 Aug;48(8):1535-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 11 anal cancers (33 percent), 11 prostate cancers, 9 cervical or endometrial cancers, 1 bladder cancer, and 1 rectal cancer.
  • Six anal or rectal strictures occurred: 4 patients had been treated for anal cancer (36 percent) and 2 patients had been treated for other cancers (9 percent).
  • None of the strictures was malignant.
  • Anal incontinence worsened in 5 patients of the 11 who had been treated for anal cancer (45 percent) and occurred in 4 of the 22 other patients (18 percent).
  • This result may be related to the high proportion of anal cancers in the series.
  • In our opinion, therefore, formalin application should be reserved for severe hemorrhagic proctitis refractory to medical treatment and should be thoroughly discussed in cases of anorectal radiation-induced stricture, prior anal incontinence, or treated anal cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Anus Diseases / etiology. Anus Neoplasms / radiotherapy. Blood Transfusion. Constriction, Pathologic / etiology. Fecal Incontinence / etiology. Female. Humans. Male. Middle Aged. Prospective Studies. Rectal Neoplasms / radiotherapy. Retreatment. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Proctitis.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2006 Apr;49(4):530-1; author reply 531-2 [16416079.001]
  • (PMID = 15933799.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


12. Middleton PF, Sutherland LM, Maddern GJ: Transanal endoscopic microsurgery: a systematic review. Dis Colon Rectum; 2005 Feb;48(2):270-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, transanal endoscopic microsurgery does appear to result in fewer recurrences than those with direct local excision in adenomas and thus may be a useful procedure for several small niches of patient types--e.g., for large benign lesions of the middle to upper third of the rectum, for T1 low-risk rectal cancers, and for palliative, not curative, use in more advanced tumors.
  • [MeSH-minor] Anal Canal. Humans

  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711865.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 87
  •  go-up   go-down


13. Bernet A, Mazelin L, Coissieux MM, Gadot N, Ackerman SL, Scoazec JY, Mehlen P: Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology; 2007 Dec;133(6):1840-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies.
  • Such a trait has been hypothesized to confer a tumor-suppressor activity.
  • Indeed, cells harboring these receptors are thought to be dependent on ligand availability for their survival, thereby inhibiting uncontrolled tumor cell proliferation.
  • We investigate here whether UNC5C acts as a tumor suppressor in colorectal malignancies.
  • Intestinal tumor progression was monitored in mice bearing both UNC5C and APC1638N mutations, and apoptosis was measured in intestinal tumors developed in UNC5C/APC1638N mutant mice.
  • RESULTS: We show here that UNC5C expression is down-regulated in a large fraction of human colorectal cancers, mainly through promoter methylation.
  • Moreover, in mice, inactivation of UNC5C is associated with increased intestinal tumor progression and a decrease in tumor cell apoptosis.
  • CONCLUSIONS: The loss of UNC5C expression observed in human colorectal cancer is a selective advantage for tumor progression, in agreement with the dependence receptor hypothesis.
  • Thus, the UNC5C dependence receptor is a tumor suppressor that regulates sporadic colorectal cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 May 9;278(19):17483-90 [12598531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4173-8 [12655055.001]
  • [Cites] Cancer Lett. 2004 Jan 8;203(1):25-33 [14670614.001]
  • [Cites] Apoptosis. 2004 Jan;9(1):37-49 [14739597.001]
  • [Cites] Cell Mol Life Sci. 2004 Aug;61(15):1854-66 [15289929.001]
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):749-55 [15258591.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3420-8 [15310786.001]
  • [Cites] Nature. 2004 Sep 2;431(7004):80-4 [15343335.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Science. 1993 Jul 16;261(5119):345-8 [8332899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73 [8090754.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):796-804 [9126737.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):838-42 [9126743.001]
  • [Cites] Cell. 1998 Mar 6;92(5):645-56 [9506519.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):801-4 [9796814.001]
  • [Cites] Cell. 1999 Jun 25;97(7):927-41 [10399920.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):179-86 [15510105.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] EMBO J. 2005 Mar 23;24(6):1192-201 [15729359.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1031-43 [16015380.001]
  • [Cites] Cell Mol Life Sci. 2005 Nov;62(22):2599-616 [16158190.001]
  • [Cites] Science. 2003 Aug 8;301(5634):843-6 [12907805.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1745-50 [10561211.001]
  • [Cites] Cell. 1999 Nov 24;99(5):451-4 [10589672.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4056-63 [10921886.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2715-22 [11387206.001]
  • [Cites] J Cell Biol. 2001 Oct 29;155(3):459-70 [11684710.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):552-6 [11932749.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Biotechniques. 2002 Apr;32(4):776-8, 780, 782 [11962599.001]
  • [Cites] Nature. 2002 May 23;417(6887):443-7 [11986622.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):306-15 [12471613.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Nat Cell Biol. 2003 Mar;5(3):216-23 [12598906.001]
  • [CommentIn] Gastroenterology. 2007 Dec;133(6):2045-9 [18054576.001]
  • (PMID = 17967459.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS45093; United States / NINDS NIH HHS / NS / R01 NS045093-05; United States / NINDS NIH HHS / NS / NS045093-02; United States / NINDS NIH HHS / NS / R01 NS045093-02; United States / NINDS NIH HHS / NS / NS045093-03; United States / NINDS NIH HHS / NS / R01 NS045093; United States / NINDS NIH HHS / NS / R01 NS045093-01; United States / NINDS NIH HHS / NS / R01 NS045093-04; United States / NINDS NIH HHS / NS / NS045093-04; United States / NINDS NIH HHS / NS / R01 NS045093-03; United States / NINDS NIH HHS / NS / NS045093-01; United States / NINDS NIH HHS / NS / NS045093-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / UNC5C protein, human
  • [Other-IDs] NLM/ NIHMS35783; NLM/ PMC2211510
  •  go-up   go-down


14. Tokcaer-Keskin Z, Dikmen ZG, Ayaloglu-Butun F, Gultekin S, Gryaznov SM, Akcali KC: The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6. Stem Cell Rev; 2010 Jun;6(2):224-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Telomerase activity is essential for the continued growth and survival of malignant cells, therefore inhibition of this activity presents an attractive target for anti-cancer therapy.
  • The telomerase inhibitor GRN163L, was shown to inhibit the growth of cancer cells both in vitro and in vivo.
  • When MSCs were treated with 1 microM GRN163L, their phenotype changed from spindle-shaped cells to rounded ones and detached from the plate surface, similar to cancer cells.
  • Quantitative-RT-PCR and immunoblotting results revealed that GRN163L holds MSCs at the G1 state of the cell cycle, with a drastic decrease in mRNA and protein levels of cyclin D1 and its cdk counterparts, cdk4 and cdk6.
  • Our study provides additional support for treating cancers by administrating GRN163L without depleting the body's stem cell pools.
  • [MeSH-minor] Animals. Blotting, Western. Cell Differentiation / drug effects. Cyclin D1 / genetics. Cyclin D1 / metabolism. Cyclin-Dependent Kinase 4 / genetics. Cyclin-Dependent Kinase 4 / metabolism. Cyclin-Dependent Kinase 6 / genetics. Cyclin-Dependent Kinase 6 / metabolism. Female. Osteogenesis / drug effects. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stem Cells. 2007 Nov;25(11):2896-902 [17901396.001]
  • [Cites] Blood. 2004 Jan 1;103(1):258-66 [12969977.001]
  • [Cites] Nat Biotechnol. 2002 Jun;20(6):592-6 [12042863.001]
  • [Cites] J Pathol. 2007 Jan;211(2):114-23 [17200948.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jul;5(7):577-84 [16773071.001]
  • [Cites] Bone. 2003 Dec;33(6):919-26 [14678851.001]
  • [Cites] Exp Cell Res. 2004 Mar 10;294(1):1-8 [14980495.001]
  • [Cites] Cell Tissue Kinet. 1970 Oct;3(4):393-403 [5523063.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1121-9 [17283146.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7866-73 [16140956.001]
  • [Cites] Ageing Res Rev. 2006 Feb;5(1):91-116 [16310414.001]
  • [Cites] Cell Res. 2008 Jul;18(7):725-32 [18574498.001]
  • [Cites] Biochimie. 2008 Jan;90(1):33-40 [18029083.001]
  • [Cites] Curr Opin Cell Biol. 2006 Jun;18(3):254-60 [16617011.001]
  • [Cites] J Anat. 2004 Feb;204(2):133-9 [15032920.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):73-81 [16319992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Dec;5(12):1571-84 [16318421.001]
  • [Cites] Mol Cancer Ther. 2009 Jul;8(7):2027-35 [19509275.001]
  • [Cites] Dev Dyn. 2004 Feb;229(2):243-58 [14745950.001]
  • [Cites] Cell Stem Cell. 2009 Mar 6;4(3):206-16 [19265660.001]
  • [Cites] Can J Physiol Pharmacol. 2009 Feb;87(2):143-50 [19234578.001]
  • [Cites] Cell. 2004 Jan 23;116(2 Suppl):S83-6, 1 p following S86 [15055591.001]
  • [Cites] BMC Cell Biol. 2008 Oct 28;9:60 [18957087.001]
  • [Cites] J Hematol Oncol. 2008 Oct 29;1:20 [18959794.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):459-67 [17001513.001]
  • [Cites] Cell. 1985 Dec;43(2 Pt 1):405-13 [3907856.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):677-83 [18231105.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1146-9 [12764382.001]
  • [Cites] Stem Cells Dev. 2009 Sep;18(7):1033-42 [19099372.001]
  • [Cites] Drug Discov Today. 2007 Aug;12(15-16):611-21 [17706542.001]
  • [Cites] Stem Cells. 2008 Sep;26(9):2287-99 [18566331.001]
  • (PMID = 20180048.001).
  • [ISSN] 1558-6804
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GRN163L peptide; 0 / Oligonucleotides; 136601-57-5 / Cyclin D1; EC 2.7.11.22 / Cdk4 protein, rat; EC 2.7.11.22 / Cdk6 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


15. Taylor JF, Robinson A, Johnson N, Marroquin-Cardona A, Brattin B, Taylor R, Phillips TD: In vitro evaluation of ferrihydrite as an enterosorbent for arsenic from contaminated drinking water. Environ Sci Technol; 2009 Jul 15;43(14):5501-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure has been linked to cancers of the bladder, lungs, skin, kidneys, nasal passages, liver, and the prostate.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 Jan;25(1):76-87 [17852392.001]
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 May;25(5):622-34 [18478481.001]
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2009 May;26(5):733-43 [19680945.001]
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 Feb;25(2):134-45 [18286403.001]
  • [Cites] Toxicol Sci. 1999 Dec;52(2 Suppl):118-26 [10630600.001]
  • [Cites] Bull World Health Organ. 2000;78(9):1093-103 [11019458.001]
  • [Cites] Chemosphere. 2000 Nov;41(10):1543-8 [11057679.001]
  • [Cites] J Am Diet Assoc. 2001 Mar;101(3):294-301 [11269606.001]
  • [Cites] Adv Exp Med Biol. 2002;504:157-71 [11922083.001]
  • [Cites] Arch Environ Contam Toxicol. 2002 Jul;43(1):56-63 [12045875.001]
  • [Cites] Environ Sci Technol. 2002 Nov 1;36(21):4562-9 [12433165.001]
  • [Cites] J Colloid Interface Sci. 2002 Nov 1;255(1):52-8 [12702367.001]
  • [Cites] Ecotoxicol Environ Saf. 2003 Sep;56(1):164-73 [12915149.001]
  • [Cites] Chem Res Toxicol. 2003 Aug;16(8):953-7 [12924922.001]
  • [Cites] Toxicol Appl Pharmacol. 1991 Apr;108(2):253-66 [2017755.001]
  • [Cites] Nat Toxins. 1995;3(4):204-13; discussion 221 [7582618.001]
  • [Cites] Semin Hematol. 1998 Jan;35(1):55-71 [9460809.001]
  • [Cites] J Toxicol Clin Toxicol. 1998;36(7):683-90 [9865236.001]
  • [Cites] J Toxicol Environ Health A. 2005 Mar 12;68(5):353-68 [15799627.001]
  • [Cites] Environ Sci Technol. 2005 Sep 15;39(18):7102-10 [16201635.001]
  • [Cites] Environ Sci Technol. 2006 Feb 15;40(4):1364-70 [16572798.001]
  • [Cites] Environ Res. 2006 May;101(1):1-10 [16171795.001]
  • [Cites] J Environ Sci Health A Tox Hazard Subst Environ Eng. 2006;41(10):2399-428 [17018421.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):281-8 [17005634.001]
  • (PMID = 19708388.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES004917-199001; United States / NIEHS NIH HHS / ES / P42 ES004917; United States / NIEHS NIH HHS / ES / P42 ES004917-199001; United States / NIEHS NIH HHS / ES / P42-ES04917
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Gastrointestinal Agents; 0 / Water Pollutants, Chemical; 39473-89-7 / ferrihydrite; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ NIHMS125421; NLM/ PMC2735052
  •  go-up   go-down


16. Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS: Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol; 2005 Dec;99(3):608-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer.
  • OBJECTIVES: Studies from the colorectal literature have shown that factors associated with anastomotic leak after colorectal resection include long surgical time (>2 h), multiple blood transfusions, and short distance to the anal verge.
  • The aim of this study was to assess the morbidity associated with en bloc resection of ovarian carcinoma with low anterior resection and anastomosis in patients undergoing primary cytoreductive surgery for advanced disease.
  • METHODS: We performed a retrospective chart review of all patients who had undergone primary cytoreduction for advanced epithelial ovarian cancer with rectosigmoid resection followed by low rectal anastomosis between January 1994 and June 2004.
  • There were 52 stage IIIC (74%) and 18 stage IV (26%) cancers.
  • CONCLUSIONS: In women undergoing primary cytoreductive surgery, the morbidity associated with en bloc resection of ovarian carcinoma with low rectosigmoid resection and anastomosis without protective ileostomy was acceptably low, with an anastomotic leak rate of less than 2%.


17. Lim ST, Levine AM: Non-AIDS-Defining Cancers and HIV Infection. Curr Infect Dis Rep; 2005 May;7(3):227-234
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Cancers and HIV Infection.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 15847726.001).
  • [ISSN] 1523-3847
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Zeller JL, Lynm C, Glass RM: JAMA patient page. Anal cancer. JAMA; 2008 Apr 23;299(16):1980
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAMA patient page. Anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430917.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Patient Education Handout
  • [Publication-country] United States
  •  go-up   go-down


19. Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, Seidel-Dugan C, Bishop WR, Dasmahapatra B: SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem; 2010 Apr 2;285(14):10198-212
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abrogation of p53 function occurs in almost all human cancers, with more than 50% of cancers harboring inactivating mutations in p53 itself.
  • Mutation of p53 is indicative of highly aggressive cancers and poor prognosis.
  • [MeSH-major] Cell Proliferation / drug effects. DNA / metabolism. Mutation / genetics. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / metabolism. Quinazolines / pharmacology. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Ubiquitination

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Feb 1;19(3):370-8 [10654936.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7701-5 [10618710.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4576-80 [11494153.001]
  • [Cites] Genes Dev. 2001 Aug 15;15(16):2069-82 [11511539.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37390-401 [11477076.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):15-30 [11602342.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):937-42 [11782540.001]
  • [Cites] Nat Med. 2002 Mar;8(3):282-8 [11875500.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):68-76 [11900253.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):233-40 [11902578.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12937-45 [11805092.001]
  • [Cites] Exp Cell Res. 2002 Jun 10;276(2):214-22 [12027451.001]
  • [Cites] Curr Mol Med. 2002 Jun;2(4):329-45 [12108946.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28446-58 [11925449.001]
  • [Cites] FEBS Lett. 2003 Feb 11;536(1-3):220-4 [12586367.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2171-81 [12612087.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] Drug Discov Today. 2003 Apr 15;8(8):347-55 [12681938.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24108-12 [12700230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7 [14595027.001]
  • [Cites] Oncogene. 2003 Nov 13;22(51):8233-45 [14614447.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1291-6 [14534297.001]
  • [Cites] J Mol Biol. 2004 Feb 6;336(1):187-96 [14741214.001]
  • [Cites] Anal Biochem. 2004 Nov 1;334(1):9-19 [15464949.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45887-96 [15308639.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] EMBO J. 1990 May;9(5):1595-602 [1691710.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Oncogene. 1995 Jan 19;10(2):389-93 [7530828.001]
  • [Cites] Anal Biochem. 1994 Dec;223(2):259-65 [7887472.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3490-4 [7627952.001]
  • [Cites] J Mol Biol. 1996 Aug 2;260(5):623-37 [8709143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14338-42 [9405613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14675-80 [9843948.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3395-402 [10207063.001]
  • [Cites] Oncogene. 1999 Jul 8;18(27):3923-9 [10435614.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R765-74 [16168122.001]
  • [Cites] Cell. 2006 Jan 13;124(1):207-19 [16413492.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):359-69 [16170349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2109-14 [16461916.001]
  • [Cites] Biochemistry. 2006 Mar 28;45(12):3925-33 [16548519.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 18;347(1):327-33 [16814250.001]
  • [Cites] Mol Cell. 2006 Jul 21;23(2):251-63 [16857591.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14616-25 [17371868.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2843-50 [18037962.001]
  • [Cites] Cancer Cell. 2009 May 5;15(5):376-88 [19411067.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6455-61 [10562557.001]
  • [Cites] Science. 1999 Dec 24;286(5449):2507-10 [10617466.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1245-56 [10713666.001]
  • (PMID = 20124408.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Chaperones; 0 / Piperazines; 0 / Quinazolines; 0 / RNA, Messenger; 0 / SCH 529074; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2856225
  •  go-up   go-down


20. Katiyar S, Casimiro MC, Dettin L, Ju X, Wagner EF, Tanaka H, Pestell RG: C-jun inhibits mammary apoptosis in vivo. Mol Biol Cell; 2010 Dec;21(23):4264-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • c-jun, which is overexpressed in a number of human cancers encodes a critical component of the AP-1 complex. c-jun has been shown to either induce or inhibit cellular apoptosis.
  • To determine the role of the endogenous c-jun gene in apoptosis, we performed mammary epithelial cell-targeted somatic deletion using floxed c-jun (c-jun(f/f)) conditional knockout mice.
  • Collectively, these studies define a pivotal role of endogenous c-jun in promoting cell survival via maintaining mitochondrial integrity and expression of the key regulators of ROS production.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 Feb 25;120(4):483-95 [15734681.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):879-89 [12791272.001]
  • [Cites] Cell. 2005 Mar 11;120(5):649-61 [15766528.001]
  • [Cites] Mol Biol Cell. 2005 Dec;16(12):5528-37 [16195353.001]
  • [Cites] Cell. 2006 Feb 10;124(3):601-13 [16469705.001]
  • [Cites] Hum Pathol. 2006 Jun;37(6):668-74 [16733206.001]
  • [Cites] Bioinformatics. 2006 Jul 15;22(14):e108-16 [16873460.001]
  • [Cites] Cell Death Differ. 2007 Feb;14(2):218-29 [16676006.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(4):1356-69 [17145782.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):191-205 [17292829.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1680-8 [17308109.001]
  • [Cites] EMBO J. 2007 Apr 4;26(7):1749-60 [17347651.001]
  • [Cites] Immunol Rev. 2007 Dec;220:8-21 [17979836.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):7007-15 [18180298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):7072-7 [20351292.001]
  • [Cites] Free Radic Biol Med. 2010 Jun 1;48(11):1485-91 [20188819.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34186-95 [10567390.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;908:219-25 [10911961.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):2005-15 [12802071.001]
  • [Cites] EMBO J. 2003 Jul 1;22(13):3356-66 [12839997.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):223-8 [12853964.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6159-73 [12917338.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):181-9 [15039755.001]
  • [Cites] Gynecol Obstet Invest. 2004;57(3):121-6 [14691341.001]
  • [Cites] Trends Cell Biol. 2004 Feb;14(2):94-101 [15102441.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):9006-18 [15456874.001]
  • [Cites] J Clin Invest. 2004 Oct;114(8):1117-27 [15489959.001]
  • [Cites] Anal Biochem. 1971 Nov;44(1):276-87 [4943714.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):389-94 [4556490.001]
  • [Cites] Biochem J. 1973 Jul;134(3):707-16 [4749271.001]
  • [Cites] IEEE Trans Biomed Eng. 1976 May;23(3):269-70 [1262040.001]
  • [Cites] Eur J Biochem. 1980 Oct;111(1):203-10 [7439185.001]
  • [Cites] Cancer Res. 1982 Feb;42(2):609-17 [6275983.001]
  • [Cites] J Biol Chem. 1991 Nov 15;266(32):22028-34 [1657986.001]
  • [Cites] Genomics. 1992 Nov;14(3):823-5 [1427917.001]
  • [Cites] Neuron. 1995 May;14(5):927-39 [7748560.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Somat Cell Mol Genet. 1995 Nov;21(6):429-41 [8600570.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5259-62 [10026130.001]
  • [Cites] Nat Genet. 1999 Mar;21(3):326-9 [10080190.001]
  • [Cites] Cell Signal. 1999 Jan;11(1):1-14 [10206339.001]
  • [Cites] Blood. 1999 May 1;93(9):2928-35 [10216087.001]
  • [Cites] Neuron. 1999 Apr;22(4):667-76 [10230788.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38388-93 [11507097.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] Mol Cell. 2002 May;9(5):1017-29 [12049738.001]
  • [Cites] Cell. 2003 Jan 24;112(2):181-92 [12553907.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10264-76 [15632193.001]
  • (PMID = 20926681.001).
  • [ISSN] 1939-4586
  • [Journal-full-title] Molecular biology of the cell
  • [ISO-abbreviation] Mol. Biol. Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075503; United States / NCI NIH HHS / CA / P30CA56036; United States / NCI NIH HHS / CA / R01CA75503; United States / NCI NIH HHS / CA / R01 CA070896; United States / NCI NIH HHS / CA / R01CA70896; United States / NCI NIH HHS / CA / R01CA86072; United States / NCI NIH HHS / CA / R01 CA086072; United States / NCI NIH HHS / CA / P30 CA056036
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Birc5 protein, mouse; 0 / Inhibitor of Apoptosis Proteins; 0 / Proto-Oncogene Proteins c-jun; 0 / Reactive Oxygen Species; 0 / Repressor Proteins; 0 / Transcription Factor AP-1; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 1.6.5.3 / Electron Transport Complex I
  • [Other-IDs] NLM/ PMC2993753
  •  go-up   go-down


21. Lu H, McDowell LM, Studelska DR, Zhang L: Glycosaminoglycans in Human and Bovine Serum: Detection of Twenty-Four Heparan Sulfate and Chondroitin Sulfate Motifs Including a Novel Sialic Acid-modified Chondroitin Sulfate Linkage Hexasaccharide. Glycobiol Insights; 2010 Feb 9;2010(2):13-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in GAG quantity and structure in blood have been indicated in cancers and other human diseases.
  • Twenty-four heparan and chondroitin sulfate motifs were identified, including linkage hexasaccharides, repeating disaccharide compositions, reducing, and non-reducing end mono-, di-, tri-, and tetrasaccharide structures.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657722.001).
  • [Journal-full-title] Glycobiology insights
  • [ISO-abbreviation] Glycobiol Insights
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM069968-04
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


22. Tian D, Das SG, Doshi JM, Peng J, Lin J, Xing C: sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett; 2008 Feb 8;259(2):198-208
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.
  • HA 14-1, a small-molecule antagonist against anti-apoptotic Bcl-2 proteins, was demonstrated to induce selective cytotoxicity toward malignant cells and to overcome drug resistance.
  • As expected from a putative antagonist against anti-apoptotic Bcl-2 proteins like HA 14-1, sHA 14-1 disrupted the binding interaction of a Bak BH3 peptide with Bcl-2 or Bcl-X(L) protein, inhibited the growth of tumor cells through the induction of apoptosis, and circumvented the drug resistance induced by the over-expression of anti-apoptotic Bcl-2 and Bcl-X(L) proteins.
  • Taken together, these findings suggest that sHA 14-1 may represent a promising candidate for the treatment of drug-resistant cancers either as a monotherapy or in combination with current cancer therapies.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2004 Feb 1;67(3):523-37 [15037204.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):19133-40 [14966123.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3607-16 [15150119.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34227-39 [15175350.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40755-61 [15262979.001]
  • [Cites] Anal Biochem. 1983 Oct 1;134(1):111-6 [6660480.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1675-87 [9501089.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):3878-85 [9670005.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Curr Biol. 1998 Sep 10;8(18):1001-8 [9740801.001]
  • [Cites] J Hepatol. 2004 Nov;41(5):799-807 [15519653.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8284-92 [15623604.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1513-24 [15634644.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Biochem J. 2005 Jul 15;389(Pt 2):527-39 [15799720.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):322-31 [16213584.001]
  • [Cites] J Med Chem. 2006 Jan 26;49(2):656-63 [16420051.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2757-64 [16510597.001]
  • [Cites] J Med Chem. 2007 Apr 19;50(8):1723-6 [17378545.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):115-23 [17349740.001]
  • [Cites] Mol Pharm. 2007 Nov-Dec;4(6):919-28 [17874842.001]
  • [Cites] Oncogene. 2006 Aug 17;25(36):5046-55 [16568081.001]
  • [Cites] Oncogene. 2006 Sep 14;25(41):5640-7 [16619034.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11348-59 [17145881.001]
  • [Cites] Apoptosis. 2007 Jan;12(1):181-93 [17136321.001]
  • [Cites] J Med Chem. 2006 Dec 28;49(26):7731-9 [17181155.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):782-91 [17234790.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):652-61 [16909121.001]
  • [Cites] Cell Growth Differ. 1999 Dec;10(12):797-804 [10616904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):183-91 [11175751.001]
  • [Cites] Dev Cell. 2001 Nov;1(5):645-53 [11709185.001]
  • [Cites] J Med Chem. 2001 Dec 6;44(25):4313-24 [11728179.001]
  • [Cites] J Am Chem Soc. 2002 Feb 20;124(7):1234-40 [11841292.001]
  • [Cites] Blood. 2002 May 1;99(9):3461-4 [11964319.001]
  • [Cites] Clin Chim Acta. 2002 Dec;326(1-2):27-45 [12417095.001]
  • [Cites] Blood. 2003 Jul 1;102(1):269-75 [12623837.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2036-45 [14513055.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2074-80 [12931228.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • (PMID = 18037229.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM062964; United States / NCI NIH HHS / CA / CA114294-03; United States / NCI NIH HHS / CA / R01 CA114294-03; United States / NCI NIH HHS / CA / R01 CA114294; United States / NIGMS NIH HHS / GM / R01GM062964
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Bax protein (53-86); 0 / Benzopyrans; 0 / Fas Ligand Protein; 0 / Nitriles; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Reactive Oxygen Species; 0 / bcl-X Protein; 0 / ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
  • [Other-IDs] NLM/ NIHMS37728; NLM/ PMC2693013
  •  go-up   go-down


23. Holley-Guthrie EA, Seaman WT, Bhende P, Merchant JL, Kenney SC: The Epstein-Barr virus protein BMRF1 activates gastrin transcription. J Virol; 2005 Jan;79(2):745-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, BMRF1 activated a reporter gene construct driven by the gastrin promoter in a variety of cell types, and this effect was mediated by two SP1/ZBP-89 binding sites in the gastrin promoter.
  • Furthermore, as the EBV genome is present in up to 10% of gastric cancers, and the different forms of gastrin are growth factors for gastrointestinal epithelium, our results suggest a mechanism by which lytic EBV infection could promote the growth of gastric cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1485-91 [10197618.001]
  • [Cites] Mol Cell Endocrinol. 1999 Sep 10;155(1-2):1-8 [10580833.001]
  • [Cites] FEBS Lett. 1999 May 7;450(3):268-72 [10359087.001]
  • [Cites] J Physiol. 1999 Jul 15;518 ( Pt 2):315-24 [10381581.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 2):R572-81 [10444566.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):6095-105 [10545120.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):351-9 [11793387.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] Scand J Gastroenterol. 2002 Mar;37(3):279-86 [11916189.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G766-75 [11960773.001]
  • [Cites] Acta Gastroenterol Belg. 2002 Jan-Mar;65(1):17-23 [12014312.001]
  • [Cites] Biochem J. 2002 Aug 1;365(Pt 3):873-9 [11971760.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):567-73 [12189558.001]
  • [Cites] Blood. 2003 Feb 1;101(3):894-902 [12393719.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):2900-14 [12771217.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G217-22 [12606305.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7062-7 [14612496.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):7264-70 [14654702.001]
  • [Cites] Microbes Infect. 2004 Apr;6(5):429-39 [15109957.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Nov;79(22):6777-81 [6294651.001]
  • [Cites] Arch Otorhinolaryngol. 1984;239(1):87-92 [6318711.001]
  • [Cites] Cell. 1988 Nov 4;55(3):427-33 [2846181.001]
  • [Cites] J Am Acad Dermatol. 1990 Jun;22(6 Pt 2):1278-82 [2163409.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1217-24 [2142019.001]
  • [Cites] Anal Biochem. 1992 Jan;200(1):81-8 [1595905.001]
  • [Cites] J Virol. 1992 Aug;66(8):5030-9 [1321285.001]
  • [Cites] EMBO J. 1993 Oct;12(10):3921-9 [8404860.001]
  • [Cites] J Virol. 1993 Dec;67(12):7648-53 [8230484.001]
  • [Cites] J Virol. 1995 Mar;69(3):1669-77 [7853503.001]
  • [Cites] J Virol. 1995 Mar;69(3):1878-86 [7853529.001]
  • [Cites] J Virol. 1995 May;69(5):2998-3006 [7707526.001]
  • [Cites] Virology. 1995 Aug 20;211(2):593-7 [7645263.001]
  • [Cites] Am J Physiol. 1995 Sep;269(3 Pt 1):G458-64 [7573458.001]
  • [Cites] J Virol. 1996 Aug;70(8):5131-42 [8764021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9194-9 [8799177.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6644-53 [8943318.001]
  • [Cites] Virology. 1997 Mar 31;230(1):22-34 [9126259.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2762-71 [9169507.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):484-94 [9417107.001]
  • [Cites] J Pathol. 1997 Nov;183(3):293-8 [9422984.001]
  • [Cites] Mamm Genome. 1998 Feb;9(2):165-7 [9457682.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):19955-64 [9685330.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] Dig Surg. 1998;15(3):209-17 [9845587.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):69-74 [9934686.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 19;262(1):113-20 [10448078.001]
  • [Cites] J Gen Virol. 1995 Jun;76 ( Pt 6):1401-8 [7782768.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Apr;278(4):C697-708 [10751319.001]
  • [Cites] Biochemistry. 2000 Apr 18;39(15):4347-57 [10757983.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12879-88 [10777586.001]
  • [Cites] Gastroenterology. 2000 Jul;119(1):162-71 [10889165.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30725-33 [10899165.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Oct;14(10):1231-47 [11012467.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Oct;14(10):1311-8 [11012476.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] J Physiol Pharmacol. 2000 Dec;51(4 Pt 1):737-49 [11192946.001]
  • [Cites] Annu Rev Physiol. 2001;63:49-76 [11181948.001]
  • [Cites] Annu Rev Physiol. 2001;63:119-39 [11181951.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):564-8 [11298626.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18082-9 [11278409.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):43713-22 [11559712.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 2001;234:123-8 [11713973.001]
  • [Cites] J Infect Dis. 2001 Dec 15;184(12):1499-507 [11740724.001]
  • [Cites] J Exp Med. 1999 May 17;189(10):1669-78 [10330446.001]
  • (PMID = 15613302.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA019014; United States / NCI NIH HHS / CA / P01-CA19014; United States / NIDDK NIH HHS / DK / R01 DK045729; United States / NIDDK NIH HHS / DK / R01 DK055732; United States / NIDDK NIH HHS / DK / R01-DK55732; United States / NIDDK NIH HHS / DK / R01-DK45729
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / DNA-Binding Proteins; 0 / Epstein-Barr virus early antigen diffuse component; 0 / Gastrins; 0 / Sp1 Transcription Factor; 0 / Transcription Factors; 0 / ZNF148 protein, human
  • [Other-IDs] NLM/ PMC538557
  •  go-up   go-down


24. Mileo AM, Piombino E, Severino A, Tritarelli A, Paggi MG, Lombardi D: Multiple interference of the human papillomavirus-16 E7 oncoprotein with the functional role of the metastasis suppressor Nm23-H1 protein. J Bioenerg Biomembr; 2006 Aug;38(3-4):215-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-risk human papillomaviruses (HPV) are linked to human cervical and other ano-genital cancers.
  • Nevertheless, E7 plays the major role in cell transformation.
  • We report a novel interaction between HPV-16 E7 and the Nm23-H1 and Nm23-H2 proteins identified in yeast by the two-hybrid system and confirmed by co-immunoprecipitation in the human keratinocyte HaCaT cell line.
  • Besides metastasis suppression, Nm23-H1 displays multiple functions in cell cycle regulation and differentiation, development, DNA regulation and caspase-independent apoptosis.
  • We propose that impairment of the multifunctional role of Nm23-H1 is an important feature consistent with the complex strategy carried out by HPV-16 E7 to promote cell transformation and tumor progression.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Human papillomavirus 16 / metabolism. Neoplasms / virology. Nucleoside-Diphosphate Kinase / metabolism. Oncogene Proteins, Viral / metabolism. Papillomavirus Infections / metabolism. Virus Integration / physiology
  • [MeSH-minor] Blotting, Western. Cell Differentiation / physiology. Cell Line. Flow Cytometry. Glutathione Transferase. Humans. Immunoprecipitation. Keratinocytes / metabolism. NM23 Nucleoside Diphosphate Kinases. Papillomavirus E7 Proteins. Two-Hybrid System Techniques. Yeasts

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1989 Jul 20;340(6230):245-6 [2547163.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17 ):18073-84 [14960567.001]
  • [Cites] Cell Death Differ. 2001 May;8(5):470-6 [11423907.001]
  • [Cites] Anal Biochem. 2002 Aug 15;307(2):341-7 [12202253.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5201-7 [12910257.001]
  • [Cites] Nat Med. 2001 Mar;7(3):350-5 [11231635.001]
  • [Cites] J Bioenerg Biomembr. 2003 Feb;35(1):67-71 [12848343.001]
  • [Cites] J Virol. 2005 Feb;79(3):1559-68 [15650182.001]
  • [Cites] J Virol. 1987 May;61(5):1686-9 [3033296.001]
  • [Cites] J Bioenerg Biomembr. 2000 Jun;32(3):247-58 [11768308.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9578-82 [1946372.001]
  • [Cites] Immunity. 1999 May;10(5):585-94 [10367904.001]
  • [Cites] J Biol Chem. 1996 Oct 11;271(41):25107-16 [8810265.001]
  • [Cites] Differentiation. 1989 Mar;40(1):42-54 [2472990.001]
  • [Cites] Exp Cell Res. 1995 Apr;217(2):267-71 [7698225.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):5525-32 [9038158.001]
  • [Cites] J Virol Methods. 2003 Dec;114(2):125-33 [14625047.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):E4 [15026478.001]
  • [Cites] Cell Growth Differ. 1992 Dec;3(12):873-9 [1472467.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Cell. 2003 Mar 7;112(5):659-72 [12628186.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3011-9 [12082531.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 6;80(3):200-4 [3346912.001]
  • [Cites] J Bioenerg Biomembr. 2003 Feb;35(1):31-40 [12848339.001]
  • [Cites] J Cell Physiol. 2000 Feb;182(2):144-9 [10623877.001]
  • [Cites] DNA Cell Biol. 1998 Dec;17(12):1047-55 [9881672.001]
  • [Cites] Adv Cancer Res. 2000;78:1-29 [10547667.001]
  • [Cites] J Exp Med. 1992 Feb 1;175(2):553-66 [1732416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10270-4 [8234288.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Cell Growth Differ. 1996 Dec;7(12):1689-95 [8959337.001]
  • [Cites] Front Biosci. 2002 Mar 01;7:d641-9 [11861215.001]
  • [Cites] J Cell Sci. 1992 Aug;102 ( Pt 4):799-805 [1385457.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4740-9 [11498796.001]
  • [Cites] J Bioenerg Biomembr. 2000 Jun;32(3):277-84 [11768311.001]
  • [Cites] Differentiation. 1993 Oct;54(3):201-17 [7505755.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7888-98 [11753671.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] J Virol. 2001 May;75(10):4705-12 [11312342.001]
  • (PMID = 17103045.001).
  • [ISSN] 0145-479X
  • [Journal-full-title] Journal of bioenergetics and biomembranes
  • [ISO-abbreviation] J. Bioenerg. Biomembr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; EC 2.5.1.18 / Glutathione Transferase; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


25. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


26. Shiraishi R, Iwakiri R, Fujise T, Kuroki T, Kakimoto T, Takashima T, Sakata Y, Tsunada S, Nakashima Y, Yanagita T, Fujimoto K: Conjugated linoleic acid suppresses colon carcinogenesis in azoxymethane-pretreated rats with long-term feeding of diet containing beef tallow. J Gastroenterol; 2010 Jun;45(6):625-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We have indicated previously that long-term feeding of beef tallow increases colorectal cancer in rats.
  • Cancer, cell proliferation, apoptosis, Wnt signaling, and the arachidonic acid cascade were examined at 44 weeks.
  • At 44 weeks, both forms of CLA attenuated multiple colon cancers, and CLA-FFA reduced the incidence of colon cancer to 50% of that seen with CLA-TG.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Arachidonic Acid / metabolism. Cattle. Cell Proliferation / drug effects. Dietary Fats / toxicity. Male. Precancerous Conditions / etiology. Rats. Rats, Sprague-Dawley. Signal Transduction / drug effects. Time Factors. Wnt Proteins / drug effects. Wnt Proteins / metabolism

  • Hazardous Substances Data Bank. TALLOW .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Apr 1;52(7 Suppl):2024s-2029s [1311987.001]
  • [Cites] N Engl J Med. 1990 Dec 13;323(24):1664-72 [2172820.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):481-6 [15182427.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5142-50 [16127743.001]
  • [Cites] J Nutr. 2003 Oct;133(10 ):3181-6 [14519807.001]
  • [Cites] Prog Lipid Res. 2001 Jul;40(4):283-98 [11412893.001]
  • [Cites] Anal Biochem. 1986 May 15;155(1):198-205 [3087234.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):1118-25 [15159244.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1509-12 [1394832.001]
  • [Cites] Cancer Lett. 2002 Mar 28;177(2):163-72 [11825663.001]
  • [Cites] Biochemistry. 1995 Apr 25;34(16):5604-9 [7727422.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):171-80 [12406562.001]
  • [Cites] BMC Cancer. 2008 Aug 14;8:237 [18702823.001]
  • [Cites] J Cell Physiol. 2005 Oct;205(1):107-13 [15880444.001]
  • [Cites] Biochim Biophys Acta. 2005 Oct 1;1736(3):244-50 [16185917.001]
  • [Cites] J Gastroenterol. 2009;44(10 ):1026-35 [19568688.001]
  • [Cites] Exp Biol Med (Maywood). 2008 Mar;233(3):310-6 [18296736.001]
  • [Cites] J Nutr. 2006 Apr;136(4):893-8 [16549447.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1185-91 [14976130.001]
  • [Cites] Toxicol In Vitro. 2005 Mar;19(2):231-42 [15649637.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4230-7 [8364919.001]
  • [Cites] J Agric Food Chem. 2000 Aug;48(8):3280-5 [10956102.001]
  • [Cites] J Biosci Bioeng. 2005 Aug;100(2):152-7 [16198256.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G357-67 [12121883.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1A):27-34 [16475675.001]
  • [Cites] J Nutr Biochem. 2006 Dec;17(12):830-6 [16563722.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3 Suppl):559S-569S [12936950.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Eur J Cancer Prev. 2006 Apr;15(2):125-33 [16523009.001]
  • [Cites] Lipids. 2001 Oct;36(10):1161-8 [11768161.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):599-602 [8112897.001]
  • [Cites] Gut. 2000 Feb;46(2):191-9 [10644312.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):404-12 [12891542.001]
  • [Cites] Prostate. 2006 Jun 1;66(8):839-46 [16491481.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):599-611 [11522744.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Jan;223(1):8-13 [10632956.001]
  • [Cites] J Nutr. 2005 Apr;135(4):778-84 [15795434.001]
  • [Cites] Cancer Lett. 2003 Jul 10;196(2):161-8 [12860274.001]
  • [Cites] Toxicol Lett. 2000 Mar 15;112-113:395-402 [10720758.001]
  • [Cites] Cancer Lett. 1987 Oct 30;37(2):147-51 [3677050.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1150-6 [17194898.001]
  • [Cites] J Am Diet Assoc. 2004 Jun;104(6):963-8, quiz 1032 [15175596.001]
  • [Cites] Nutr Cancer. 2007;59(1):82-91 [17927506.001]
  • (PMID = 20143104.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Fats; 0 / Linoleic Acids, Conjugated; 0 / Wnt Proteins; 27YG812J1I / Arachidonic Acid; 98HPY76U4W / tallow; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


27. Moore DH: Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one? Gynecol Oncol; 2009 Jun;113(3):379-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?
  • The incorporation of radiation therapy and eventually chemotherapy in the primary treatment of vulva cancer also represents a slow evolution in clinical management.
  • The addition of chemotherapy concurrent to radiation therapy for the treatment of vulvar carcinoma was heavily influenced by advances in the treatment of cervical cancer, and squamous cell carcinoma of the anal canal.
  • On the basis of many good phase II studies but no randomized controlled trials in the disease, chemoradiation therapy is now inherent to the clinical management of vulvar carcinoma.
  • The rarity of vulva cancer precludes prospective randomized clinical trials in the absence of international collaboration.
  • Nonetheless, patients with locally advanced vulva cancer have derived considerable benefit from chemoradiation studies in other related tumor sites, and will continue to do so in the future.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232700.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 77
  •  go-up   go-down


28. Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J: Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer; 2010;10:553
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.
  • BACKGROUND: Matrix metalloproteinases (MMPs) are involved in the degradation of protein components of the extracellular matrix and thus play an important role in tumor invasion and metastasis.
  • Their expression is related to the progression of gynecological cancers (e.g. endometrial, cervical or ovarian carcinoma).
  • In this study we investigated the expression pattern of the 23 MMPs, currently known in humans, in different gynecological cancer cell lines.
  • METHODS: In total, cell lines from three endometrium carcinomas (Ishikawa, HEC-1-A, AN3 CA), three cervical carcinomas (HeLa, Caski, SiHa), three chorioncarcinomas (JEG, JAR, BeWo), two ovarian cancers (BG-1, OAW-42) and one teratocarcinoma (PA-1) were examined.
  • RESULTS: We demonstrated that the cell lines examined can constitutively express a wide variety of MMPs on mRNA and protein level.
  • While MMP-2, -11, -14 and -24 were widely expressed, no expression was seen for MMP-12, -16, -20, -25, -26, -27 in any of the cell lines.
  • A broad range of 16 MMPs could be found in the PA1 cells and thus this cell line could be used as a positive control for general MMP experiments.
  • While the three cervical cancer cell lines expressed 10-14 different MMPs, the median expression in endometrial and choriocarcinoma cells was 7 different enzymes.
  • The two investigated ovarian cancer cell lines showed a distinctive difference in the number of expressed MMPs (2 vs. 10).
  • CONCLUSIONS: Ishikawa, Caski, OAW-42 and BeWo cell lines could be the best choice for all future experiments on MMP regulation and their role in endometrial, cervical, ovarian or choriocarcinoma development, whereas the teratocarcinoma cell line PA1 could be used as a positive control for general MMP experiments.
  • [MeSH-minor] Cell Line, Tumor. Female. Gene Expression Profiling. HeLa Cells. Humans. Neoplasm Invasiveness. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2009;9:188 [19531263.001]
  • [Cites] Mol Hum Reprod. 2002 Jul;8(7):659-66 [12087081.001]
  • [Cites] Hum Cell. 2002 Jun;15(2):81-95 [12227503.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):79-89 [12491508.001]
  • [Cites] Hum Cell. 2002 Sep;15(3):104-17 [12703541.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):145-52 [12784993.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):453-9 [12798711.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):297-304 [12893190.001]
  • [Cites] Eur J Pharm Sci. 2003 Aug;19(5):433-42 [12907294.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):661-70 [15350356.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):827-35 [15459663.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1231-6 [4299001.001]
  • [Cites] J Clin Endocrinol Metab. 1971 May;32(5):683-7 [5103722.001]
  • [Cites] Acta Endocrinol Suppl (Copenh). 1971;153:137-53 [5314233.001]
  • [Cites] Obstet Gynecol. 1971 Dec;38(6):945-9 [4942173.001]
  • [Cites] Ann N Y Acad Sci. 1971 Jan 28;172(10):288-98 [5289994.001]
  • [Cites] Am J Obstet Gynecol. 1972 Dec 15;114(8):1012-9 [4673779.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Science. 1977 Jun 24;196(4297):1456-8 [867042.001]
  • [Cites] J Natl Cancer Inst. 1977 Jul;59(1):221-6 [327080.001]
  • [Cites] Int J Cancer. 1980 Jan 15;25(1):19-32 [6931103.001]
  • [Cites] J Natl Cancer Inst. 1984 Mar;72(3):513-21 [6583437.001]
  • [Cites] Cancer Genet Cytogenet. 1984 Aug;12(4):321-7 [6744227.001]
  • [Cites] Am J Pathol. 1985 Jun;119(3):361-6 [2990217.001]
  • [Cites] Virology. 1985 Sep;145(2):313-8 [2992153.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1985 Jul;37(7):1103-11 [4031568.001]
  • [Cites] J Virol. 1987 Apr;61(4):962-71 [3029430.001]
  • [Cites] Can J Physiol Pharmacol. 1999 Jul;77(7):465-80 [10535707.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(5-6):367-70 [10609496.001]
  • [Cites] Int J Cancer. 2000 Aug 1;87(3):336-42 [10897037.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):673-81 [10995877.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10134-44 [11121398.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):442-9 [11520138.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1466-75 [11920503.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):103-7 [11925127.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):565-9 [11956628.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):315-9 [12001993.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):280-8 [2910432.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):267-75 [7812956.001]
  • [Cites] Matrix Biol. 1998 Mar;16(8):483-96 [9550265.001]
  • [Cites] Exp Cell Res. 1998 Jul 10;242(1):18-26 [9665798.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Sep;34(8):649-54 [9769151.001]
  • [Cites] Int J Gynecol Pathol. 1998 Oct;17(4):295-301 [9785129.001]
  • [Cites] J Natl Cancer Inst. 1964 Sep;33:441-56 [14207855.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8229-34 [15623598.001]
  • [Cites] J Cell Sci. 2005 Mar 15;118(Pt 6):1185-95 [15728252.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6543-50 [16061633.001]
  • [Cites] Reprod Biol Endocrinol. 2005;3:74 [16384532.001]
  • [Cites] Cardiovasc Res. 2006 Feb 15;69(3):562-73 [16405877.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Aug;132(8):505-13 [16788844.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1794-800 [17009974.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1911-7 [17009991.001]
  • [Cites] Biochem Cell Biol. 2006 Oct;84(5):713-9 [17167534.001]
  • [Cites] Histopathology. 2007 Feb;50(3):348-57 [17257130.001]
  • [Cites] Mol Carcinog. 2007 Feb;46(2):130-43 [17131304.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 [17318226.001]
  • [Cites] Placenta. 2007 Apr;28(4):298-304 [16750851.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):337-50 [17639049.001]
  • [Cites] Neurosci Res. 2008 Jan;60(1):40-9 [17980449.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):533-42 [18177928.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Aug;62(3):483-9 [18004570.001]
  • (PMID = 20942921.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2964638
  •  go-up   go-down


29. Hao J, Serohijos AW, Newton G, Tassone G, Wang Z, Sgroi DC, Dokholyan NV, Basilion JP: Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers. PLoS Comput Biol; 2008 Aug 01;4(8):e1000138
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers.
  • Cysteine-rich intestinal protein 1 (CRIP1) has been identified as a novel marker for early detection of cancers.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 2002 Oct 25;323(3):417-23 [12381298.001]
  • [Cites] Structure. 2007 Dec;15(12):1567-76 [18073107.001]
  • [Cites] Anal Biochem. 1999 Nov 1;275(1):62-73 [10542110.001]
  • [Cites] J Mol Biol. 2000 Apr 28;298(2):313-28 [10764600.001]
  • [Cites] J Am Chem Soc. 2001 May 2;123(17):3986-94 [11457149.001]
  • [Cites] J Med Chem. 2001 Oct 25;44(22):3572-81 [11606121.001]
  • [Cites] J Mol Biol. 2001 Oct 19;313(2):317-42 [11800560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5896-901 [11972061.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Nat Struct Biol. 2002 Aug;9(8):621-7 [12080331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):74-9 [12502784.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4463-8 [12679523.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1927-35 [12702585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Proteins. 2003 Jul 1;52(1):68-73 [12784369.001]
  • [Cites] Proteins. 2003 Jul 1;52(1):80-7 [12784371.001]
  • [Cites] Curr Opin Struct Biol. 2003 Jun;13(3):389-95 [12831892.001]
  • [Cites] J Cell Biochem. 2003 Oct 15;90(3):509-17 [14523985.001]
  • [Cites] J Comput Chem. 2004 Feb;25(3):393-411 [14696074.001]
  • [Cites] Curr Opin Chem Biol. 2004 Feb;8(1):91-7 [15036162.001]
  • [Cites] J Mol Biol. 2004 Mar 5;336(5):1223-38 [15037081.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):100-12 [15305381.001]
  • [Cites] Mol Cancer Res. 2004 Aug;2(8):477-87 [15328374.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6378-82 [2201029.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 30;205(1):497-505 [7999070.001]
  • [Cites] J Immunol. 1995 Jan 15;154(2):893-906 [7529290.001]
  • [Cites] J Mol Biol. 1996 Mar 22;257(1):153-74 [8632452.001]
  • [Cites] Gene. 1996 May 24;171(1):1-8 [8675015.001]
  • [Cites] Science. 1996 Jul 26;273(5274):458-64 [8662529.001]
  • [Cites] Proteins. 1996 Nov;26(3):262-70 [8953648.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):101-6 [9125110.001]
  • [Cites] Protein Expr Purif. 1997 Apr;9(3):379-87 [9126610.001]
  • [Cites] Protein Sci. 1997 Jun;6(6):1293-301 [9194189.001]
  • [Cites] Eur J Biochem. 1998 Jan 15;251(1-2):155-63 [9492279.001]
  • [Cites] Mol Immunol. 1997 Nov-Dec;34(16-17):1215-26 [9566768.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2417-25 [9622083.001]
  • [Cites] Virology. 2005 Jan 20;331(2):269-91 [15629771.001]
  • [Cites] J Proteome Res. 2006 Jan;5(1):32-43 [16396493.001]
  • [Cites] PLoS Comput Biol. 2006 Jul 7;2(7):e85 [16839198.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1829-36 [16721809.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Feb;34(2):267-73 [16909226.001]
  • [Cites] Bioorg Med Chem. 2007 Apr 1;15(7):2789-96 [17293116.001]
  • [Cites] Nat Methods. 2007 Jun;4(6):466-7 [17538626.001]
  • [Cites] Nat Struct Biol. 2003 Jan;10(1):45-52 [12459719.001]
  • (PMID = 18670594.001).
  • [ISSN] 1553-7358
  • [Journal-full-title] PLoS computational biology
  • [ISO-abbreviation] PLoS Comput. Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM080742; United States / NIGMS NIH HHS / GM / R01GM080742-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRIP1 protein, human; 0 / Carrier Proteins; 0 / LIM Domain Proteins; 0 / Ligands; 0 / Peptide Library; 0 / Peptides
  • [Other-IDs] NLM/ PMC2453235
  •  go-up   go-down


30. Birkenkamp-Demtroder K, Mansilla F, Sørensen FB, Kruhøffer M, Cabezón T, Christensen LL, Aaltonen LA, Verspaget HW, Ørntoft TF: Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Mol Oncol; 2007 Sep;1(2):181-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro.
  • Keratin23 impaired the proliferation of human colon cancer cells significantly, leading to cell death in microsatellite-instable but not microsatellite-stable cell lines, while COS7 cells experienced multiple nuclei and apoptosis.
  • In conclusion, Keratin23 expression is a novel and important difference between microsatellite-stable and microsatellite-instable colon cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Proliferation. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Keratins, Type I / biosynthesis. Microsatellite Instability. Neoplasm Proteins / biosynthesis. Phosphoproteins / biosynthesis
  • [MeSH-minor] Animals. Apoptosis / genetics. CCAAT-Enhancer-Binding Proteins / genetics. CCAAT-Enhancer-Binding Proteins / metabolism. COS Cells. Cell Nucleus / genetics. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Survival / genetics. Cercopithecus aethiops. Female. Gene Expression Profiling. Golgi Apparatus / genetics. Golgi Apparatus / metabolism. Golgi Apparatus / pathology. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Transcription, Genetic / genetics. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histochem Cell Biol. 2002 Jul;118(1):35-40 [12122445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2240-8 [15956967.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] J Biol Chem. 2006 Sep 29;281(39):29245-55 [16835220.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):209-10 [12867603.001]
  • [Cites] Differentiation. 2004 Dec;72(9-10):527-40 [15617563.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):181-95 [19383294.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] Trends Biochem Sci. 2006 Jul;31(7):383-94 [16782342.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Gut. 2005 Mar;54(3):374-84 [15710986.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1364-73 [2851102.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):534-44 [15671042.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Anal Bioanal Chem. 2006 Nov;386(6):1603-12 [17043799.001]
  • [Cites] J Cell Biol. 2006 Jul 17;174(2):169-74 [16831889.001]
  • [Cites] BMC Cancer. 2002 Dec 26;2:37 [12502432.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13548-58 [16533812.001]
  • [Cites] Neuroendocrinology. 2005;82(2):121-38 [16449819.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] J Electron Microsc (Tokyo). 1991 Feb;40(1):24-8 [1865155.001]
  • [Cites] Trends Cell Biol. 2005 Nov;15(11):608-17 [16202602.001]
  • [Cites] Eur J Biochem. 1991 Apr 23;197(2):281-90 [1709097.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26792-8 [11356849.001]
  • [Cites] Oncogene. 2004 May 27;23(25):4362-70 [15048075.001]
  • [Cites] Oncogene. 2004 Aug 19;23(37):6218-25 [15208663.001]
  • [Cites] Cancer Sci. 2006 Mar;97(3):167-74 [16542212.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):217-22 [12469172.001]
  • [Cites] Nucleic Acids Res. 1998 Jan 1;26(1):362-7 [9399875.001]
  • [Cites] Cell Mol Life Sci. 2003 Jan;60(1):56-71 [12613658.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):123-35 [11135429.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23 ):8332-40 [16322293.001]
  • [Cites] J Cell Biol. 1997 Sep 22;138(6):1379-94 [9298992.001]
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16453-61 [16608857.001]
  • (PMID = 19383294.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / KRT23 protein, human; 0 / Keratins, Type I; 0 / Neoplasm Proteins; 0 / Phosphoproteins
  •  go-up   go-down


31. Simatherai D, Bradshaw CS, Fairley CK, Bush M, Heley S, Chen MY: What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect; 2009 Apr;85(2):148-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When informed of the increased risk of anal cancer among MSM, 47% of MSM indicated that they would be willing to pay $A450 for the vaccine course.
  • [MeSH-major] Anus Neoplasms / psychology. Papillomavirus Infections / psychology. Papillomavirus Vaccines. Patient Acceptance of Health Care / psychology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153110.001).
  • [ISSN] 1472-3263
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


32. Li F, Li M, Xiao Z, Zhang P, Li J, Chen Z: Construction of a nasopharyngeal carcinoma 2D/MS repository with Open Source XML database--Xindice. BMC Bioinformatics; 2006;7:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Construction of a nasopharyngeal carcinoma 2D/MS repository with Open Source XML database--Xindice.
  • Nasopharyngeal carcinoma (NPC) is one of the most common cancers in southern China and Southeast Asia, which has marked geographic and racial differences in incidence.
  • Although there are some cancer proteome databases now, there is still no NPC proteome database.
  • [MeSH-major] Carcinoma / metabolism. Computational Biology / methods. Gene Expression Regulation, Neoplastic. Gene Library. Mass Spectrometry / methods. Nasopharyngeal Neoplasms / metabolism

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 1999 Nov 1;71(21):4981-8 [10565287.001]
  • [Cites] BMC Bioinformatics. 2005;6:235 [16188029.001]
  • [Cites] Curr Opin Investig Drugs. 2001 Apr;2(4):437-9 [11565999.001]
  • [Cites] Proteomics. 2002 May;2(5):481-5 [11987122.001]
  • [Cites] Genome Biol. 2002 Aug 23;3(9):RESEARCH0046 [12225585.001]
  • [Cites] Nat Biotechnol. 2003 Mar;21(3):247-54 [12610571.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):193-7 [12634792.001]
  • [Cites] Proteomics. 2004 Feb;4(2):490-1 [14760721.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):471-2 [15085804.001]
  • [Cites] BMC Bioinformatics. 2004 Jan 29;5:9 [15005801.001]
  • [Cites] Bioinformatics. 2004 Jul 10;20(10):1583-90 [15145818.001]
  • [Cites] BMC Genomics. 2004 Sep 17;5:68 [15377392.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2463-5 [15073025.001]
  • [Cites] Nat Biotechnol. 2004 Nov;22(11):1459-66 [15529173.001]
  • [Cites] Bioinformatics. 2001 Feb;17(2):115-25 [11238067.001]
  • (PMID = 16403238.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1351203
  •  go-up   go-down


33. Deschoolmeester V, Boeckx C, Baay M, Weyler J, Wuyts W, Van Marck E, Peeters M, Lardon F, Vermorken JB: KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer; 2010 Nov 9;103(10):1627-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.
  • BACKGROUND: The development of targeted therapies has created a pressing clinical need for molecular characterisation of cancers.
  • In this retrospective study, high-resolution melting analysis (HRMA) was validated and implemented for screening of 164 colorectal cancer (CRC) patients to detect KRAS hot-spot mutations and to evaluate its prognostic value.
  • METHODS: After establishing its sensitivity, HRMA was validated on seven cell lines and inter- and intra-variation were analysed.
  • In the Cox regression analysis, only when colon and rectal cancer were analysed separately, KRAS mutation was a negative predictor for OS in patients with rectal cancer and DFS in those with stage II colon cancer.
  • The KRAS mutation came forward as a negative predictive factor for OS in patients with rectal cancer and for DFS in stage II colon cancer patients.
  • [MeSH-minor] Cell Line, Tumor. Colonic Neoplasms / genetics. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. DNA Primers. DNA, Neoplasm / genetics. Genetic Variation. Humans. Mass Screening / methods. Mutation. Nucleic Acid Denaturation. Polymerase Chain Reaction. Prognosis. Rectal Neoplasms / genetics. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Regression Analysis. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Sep;81(2):190-3 [10496341.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1221-5 [15547741.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv50-55 [15923430.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] J Clin Lab Anal. 2006;20(2):52-61 [16538640.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):158-63 [16953233.001]
  • [Cites] BMC Cancer. 2006;6:295 [17184525.001]
  • [Cites] Pathol Res Pract. 2007;203(7):489-97 [17629419.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1405-10 [18505087.001]
  • [Cites] BMC Cancer. 2008;8:142 [18495026.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):247-53 [18628094.001]
  • [Cites] Gene. 2008 Nov 1;423(2):188-93 [18692554.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2288-95 [18707864.001]
  • [Cites] Gut. 2009 Jan;58(1):90-6 [18832519.001]
  • [Cites] Oncologist. 2009 Jan;14(1):29-39 [19144681.001]
  • [Cites] J Mol Diagn. 2009 Mar;11(2):140-7 [19213871.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1155-61 [19190129.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1130-6 [19124802.001]
  • [Cites] Clin Adv Hematol Oncol. 2009 Jan;7(1):45-53, 64 [19274041.001]
  • [Cites] J Hematol Oncol. 2009;2:9 [19236713.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):262-71 [19117687.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2091-6 [19188670.001]
  • [Cites] Oncologist. 2009 May;14(5):478-88 [19411318.001]
  • [Cites] BMC Cancer. 2009;9:145 [19439077.001]
  • [Cites] Cell Oncol. 2009;31(3):161-7 [19478384.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2622-9 [19398573.001]
  • [Cites] Pathol Res Pract. 2009;205(12):858-62 [19679400.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7322-9 [19934290.001]
  • [Cites] Am J Ther. 2009 Nov-Dec;16(6):554-61 [19352138.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • [Cites] Oncologist. 2010;15(4):390-404 [20350999.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3A):1695-701 [10928094.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 [11097226.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23 [11535541.001]
  • [Cites] Curr Pharm Des. 2001 Nov;7(16):1581-94 [11562300.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1438-46 [12196370.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):891-904 [12507199.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1026-38 [12853343.001]
  • [Cites] Int J Colorectal Dis. 2004 Jan;19(1):23-42 [12827409.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1275-91 [15382104.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1136-41 [1551522.001]
  • [Cites] Arch Surg. 1993 May;128(5):526-31; discussion 531-2 [8489386.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3376-8 [8012953.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):491-7 [8814697.001]
  • [Cites] Am J Surg. 1998 Mar;175(3):198-202 [9560119.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • (PMID = 20959826.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2990591
  •  go-up   go-down


34. Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, McClelland M: Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia; 2005 Aug;7(8):748-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey of differentially methylated promoters in prostate cancer cell lines.
  • DNA methylation and copy number in the genomes of three immortalized prostate epithelial and five cancer cell lines (LNCaP, PC3, PC3M, PC3M-Pro4, and PC3M-LN4) were compared using a microarray-based technique.
  • Of 2732 promoter sequences on a test array, 504 (18.5%) showed differential hybridization between immortalized prostate epithelial and cancer cell lines.
  • Among candidate hypermethylated genes in cancer-derived lines, there were eight (CD44, CDKN1A, ESR1, PLAU, RARB, SFN, TNFRSF6, and TSPY) previously observed in prostate cancer and 13 previously known methylation targets in other cancers (ARHI, bcl-2, BRCA1, CDKN2C, GADD45A, MTAP, PGR, SLC26A4, SPARC, SYK, TJP2, UCHL1, and WIT-1).
  • The majority of genes that appear to be both differentially methylated and differentially regulated between prostate epithelial and cancer cell lines are novel methylation targets, including PAK6, RAD50, TLX3, PIR51, MAP2K5, INSR, FBN1, and GG2-1, representing a rich new source of candidate genes used to study the role of DNA methylation in prostate tumors.


35. Chiao EY: Duration of anal human papillomavirus infection among immunocompetent women: clues to anal cancer epidemiology and possible prevention strategies. Clin Infect Dis; 2009 Mar 1;48(5):547-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duration of anal human papillomavirus infection among immunocompetent women: clues to anal cancer epidemiology and possible prevention strategies.
  • [MeSH-major] Anal Canal / virology. Anus Neoplasms / etiology. Neoplasms, Squamous Cell / etiology. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Papillomavirus Infections / virology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Infect Dis. 2009 Mar 1;48(5):536-46 [19191636.001]
  • (PMID = 19191637.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23CA124318
  • [Publication-type] Comment; Editorial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


36. Cranston RD, Hart SD, Gornbein JA, Hirschowitz SL, Cortina G, Moe AA: The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men. Int J STD AIDS; 2007 Feb;18(2):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men.
  • Due to the increasing incidence of anal cancer in HIV-positive men who have sex with men, and the potential to detect and treat high-grade anal dysplasia--the putative anal cancer precursor--we have introduced an anal cytology screening service.
  • Patients with abnormal anal cytology have follow-up high-resolution anoscopy (HRA) with biopsy of lesions clinically suspicious for high-grade dysplasia.
  • One hundred and sixty-four (67%) men had abnormal anal cytology, and 93 of them had follow-up HRA and anal biopsy.
  • The positive predictive value for any anal cytological abnormality to predict any degree of anal dysplasia was 95.7+/-2.1%, and for any anal cytological abnormality to predict high-grade anal dysplasia was 55.9+/-5.1%.
  • Abnormal anal cytology was highly predicative of anal dysplasia on biopsy.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms. Carcinoma, Squamous Cell. HIV Infections / complications. Homosexuality, Male
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / epidemiology. Adult. Aged. Biopsy. Cytological Techniques. Humans. Male. Middle Aged. Predictive Value of Tests. Prevalence

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331275.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Placzek EA, Plebanek MP, Lipchik AM, Kidd SR, Parker LL: A peptide biosensor for detecting intracellular Abl kinase activity using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem; 2010 Feb 1;397(1):73-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many cancers are characterized by changes in protein phosphorylation as a result of kinase dysregulation.
  • This straightforward methodology could eventually provide a new tool for detecting kinase activity and inhibitor drug response in cancer cells that overexpress oncogenic kinases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Biochemistry. 1996 Aug 20;35(33):10634-40 [8718852.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] J Am Chem Soc. 2005 Jun 1;127(21):7684-5 [15913351.001]
  • [Cites] Anal Biochem. 2005 Dec 1;347(1):67-76 [16236241.001]
  • [Cites] Analyst. 2006 Oct;131(10):1097-104 [17003856.001]
  • [Cites] Mol Biol Cell. 2007 Oct;18(10):4143-54 [17686996.001]
  • [Cites] Mol Biosyst. 2007 Nov;3(11):759-65 [17940658.001]
  • [Cites] J Mass Spectrom. 2008 Apr;43(4):518-27 [18064576.001]
  • [Cites] Nature. 2008 Jun 19;453(7198):1132-6 [18463638.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 2;100(13):926-39 [18577747.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9809-16 [19047160.001]
  • [Cites] Chem Biol. 2009 Jan 30;16(1):48-57 [19171305.001]
  • [Cites] J Biol Chem. 2009 Feb 6;284(6):3370-8 [19047062.001]
  • [Cites] Cell Signal. 2009 Aug;21(8):1308-16 [19344757.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Cell. 2002 Jan 25;108(2):247-59 [11832214.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):13-5 [12086882.001]
  • [Cites] Cell. 2003 Mar 21;112(6):859-71 [12654251.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):41-9 [12694725.001]
  • [Cites] Acc Chem Res. 2003 Jun;36(6):393-400 [12809525.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):35-43 [14676625.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44 [14708008.001]
  • [Cites] Biochemistry. 2004 Jul 6;43(26):8528-40 [15222764.001]
  • [Cites] EMBO J. 1985 Mar;4(3):683-6 [3859408.001]
  • [Cites] Cancer Invest. 1989;7(2):195-203 [2676087.001]
  • [Cites] Science. 1990 Feb 16;247(4944):824-30 [2406902.001]
  • [Cites] Nature. 1995 Feb 9;373(6514):536-9 [7845468.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):579-96 [15722165.001]
  • (PMID = 19818327.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K99 CA127161-02; United States / NCI NIH HHS / CA / R00 CA127161; United States / NCI NIH HHS / CA / K99 CA127161-01A2; United States / NCI NIH HHS / CA / K99CA127161A; United States / NCI NIH HHS / CA / CA127161-02; United States / NCI NIH HHS / CA / K99 CA127161
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Peptides; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl
  • [Other-IDs] NLM/ NIHMS151624; NLM/ PMC2808441
  •  go-up   go-down


38. Distler U, Souady J, Hülsewig M, Drmić-Hofman I, Haier J, Friedrich AW, Karch H, Senninger N, Dreisewerd K, Berkenkamp S, Schmidt MA, Peter-Katalinić J, Müthing J: Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS One; 2009;4(8):e6813
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer.
  • BACKGROUND: Despite progress in adjuvant chemotherapy in the recent decades, pancreatic and colon cancers remain common causes of death worldwide.
  • Bacterial toxins, which specifically bind to cell surface-exposed glycosphingolipids, are a potential novel therapy.
  • METHODOLOGY/PRINCIPAL FINDINGS: Tissue lipid extracts of matched pairs of cancerous and adjacent normal tissue from 21 pancreatic and 16 colon cancer patients were investigated with thin-layer chromatography overlay assay combined with a novel mass spectrometry approach.
  • Gb3Cer/CD77 was localized by immunofluorescence microscopy of cryosections from malignant and corresponding healthy tissue samples.
  • 62% of pancreatic and 81% of colon adenocarcinomas showed increased Gb3Cer/CD77 expression, whereas 38% and 19% of malignant pancreas and colon tissue, respectively, did not, indicating an association of this marker with neoplastic transformation.
  • Also, Gb3Cer/CD77 was associated with poor differentiation (G>2) in pancreatic cancer (P = 0.039).
  • Mass spectrometric analysis evidenced enhanced expression of Gb3Cer/CD77 with long (C24) and short chain fatty acids (C16) in malignant tissues and pointed to the presence of hydroxylated fatty acid lipoforms, which are proposed to be important for receptor targeting.
  • Immunohistology of tissue cryosections indicated tumor-association of these receptors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Colorectal Cancer. 2004 Jun;4 Suppl 1:S22-8 [15212702.001]
  • [Cites] Methods Enzymol. 2005;405:300-69 [16413319.001]
  • [Cites] J Med Microbiol. 1971 Aug;4(3):301-5 [4940299.001]
  • [Cites] J Biol Chem. 1984 Apr 10;259(7):4672-80 [6707026.001]
  • [Cites] Nature. 1985 Mar 7-13;314(6006):53-7 [2579340.001]
  • [Cites] Carbohydr Res. 1988 Jul 15;178:121-44 [3191505.001]
  • [Cites] J Biol Chem. 1994 Apr 15;269(15):11138-46 [8157640.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6996-7000 [7624357.001]
  • [Cites] Trends Microbiol. 1996 Apr;4(4):147-53 [8728608.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Clin Infect Dis. 2006 Nov 1;43(9):1160-7 [17029135.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1321-6 [16995873.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):670-5 [18046403.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):106-12 [18026191.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):253-67, ix [18313549.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Anal Chem. 2008 Mar 15;80(6):1835-46 [18278947.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):525-31 [17980710.001]
  • [Cites] Glycoconj J. 2008 May;25(4):291-304 [18176841.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4535-6 [18353979.001]
  • [Cites] PLoS One. 2008;3(4):e1925 [18382692.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2033-41 [18645013.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2498-508 [18687997.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2464-75 [18723492.001]
  • [Cites] Thromb Haemost. 2009 Feb;101(2):252-64 [19190807.001]
  • [Cites] Biosci Rep. 1999 Oct;19(5):345-54 [10763802.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1828-36 [10760759.001]
  • [Cites] Toxicon. 2001 Nov;39(11):1629-35 [11595626.001]
  • [Cites] Chem Rev. 2002 Feb;102(2):555-78 [11841254.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):304-11 [12082546.001]
  • [Cites] Neurochem Res. 2002 Aug;27(7-8):807-13 [12374217.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2937-45 [16540641.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5901-9 [16740730.001]
  • [Cites] Chem Rev. 2006 Jun;106(6):2111-25 [16771445.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7230-6 [16849571.001]
  • [Cites] Cell Mol Life Sci. 2006 Aug;63(16):1850-66 [16799768.001]
  • [Cites] BioDrugs. 2003;17(3):155-67 [12749752.001]
  • [Cites] Semin Cell Dev Biol. 2004 Aug;15(4):397-408 [15207830.001]
  • [Cites] Nature. 1997 Jun 5;387(6633):569-72 [9177342.001]
  • [Cites] Methods Mol Biol. 1998;76:183-95 [9664354.001]
  • [Cites] Glycobiology. 1999 May;9(5):459-68 [10207178.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2901-10 [10515895.001]
  • [Cites] FASEB J. 2005 Jan;19(1):103-5 [15520251.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1073-86 [15781103.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2524-32 [15784599.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19695-703 [15743770.001]
  • [Cites] Gene Ther. 2005 Sep;12(18):1360-8 [15902276.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1354-5 [16230091.001]
  • [Cites] Int J Med Microbiol. 2005 Oct;295(6-7):357-71 [16238013.001]
  • [Cites] Int J Med Microbiol. 2005 Oct;295(6-7):405-18 [16238016.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(24):3659-65 [16285017.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 30;1746(3):314-21 [16153723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19087-92 [16365318.001]
  • [Cites] J Biol Chem. 1971 Mar 10;246(5):1192-200 [5545063.001]
  • (PMID = 19714252.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide
  • [Other-IDs] NLM/ PMC2730034
  •  go-up   go-down


39. Dharmasiri U, Witek MA, Adams AA, Soper SA: Microsystems for the capture of low-abundance cells. Annu Rev Anal Chem (Palo Alto Calif); 2010;3:409-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For example, the clinical utility of circulating tumor cells (CTCs) in peripheral blood is recognized as a viable biomarker for the management of various cancers, in which the clinically relevant number of CTCs per 7.5 ml of blood is two to five.
  • Although there are several methods for isolating rare cells from a variety of heterogeneous samples, such as immunomagnetic-assisted cell sorting and fluorescence-activated cell sorting, they are fraught with challenges.
  • Such approaches involve reductions in target-cell loss, process automation, and minimization of contamination issues.
  • In this review, we introduce different application areas requiring rare cell analysis, conventional techniques for their selection, and finally microsystem approaches for low-abundance-cell isolation and enumeration.
  • [MeSH-major] Cell Separation / methods
  • [MeSH-minor] Biomarkers, Tumor / blood. Flow Cytometry. Humans. Microfluidic Analytical Techniques. Neoplasms / blood. Neoplastic Cells, Circulating

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20636049.001).
  • [ISSN] 1936-1335
  • [Journal-full-title] Annual review of analytical chemistry (Palo Alto, Calif.)
  • [ISO-abbreviation] Annu Rev Anal Chem (Palo Alto Calif)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33 CA099246-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Lin A, Ben-Josef E: Intensity-modulated radiation therapy for the treatment of anal cancer. Clin Colorectal Cancer; 2007 Nov;6(10):716-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for the treatment of anal cancer.
  • PATIENTS AND METHODS: A 9-field, non-coplanar, 1-cm beamlet IMRT plan was designed for 9 patients who were previously treated for anal cancer with conventional field arrangements.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039425.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Toma MI, Friedrich K, Meyer W, Fröhner M, Schneider S, Wirth M, Baretton GB: Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer. Anal Quant Cytol Histol; 2010 Feb;32(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer.
  • OBJECTIVE: To analyze the centrosomal abnormalities in correlation with DNA ploidy and clinicopathologic data in prostate cancer.
  • STUDY DESIGN: Formalin-fixed, paraffin-embedded material from 63 prostate cancers (PCa) and 10 normal control cases were studied.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701082.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / DNA, Neoplasm; 0 / Tubulin; 0 / pericentrin
  •  go-up   go-down


42. Mao Y, Zhao X, Wang S, Cheng Y: Urinary nucleosides based potential biomarker selection by support vector machine for bladder cancer recognition. Anal Chim Acta; 2007 Aug 13;598(1):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary nucleosides based potential biomarker selection by support vector machine for bladder cancer recognition.
  • BACKGROUND: Urinary nucleosides are potential biomarkers for many kinds of cancers.
  • But up to now, it has been little focused in bladder cancer recognition.
  • The aim of present study is try to validate the potential of urinary nucleoside as biomarker for bladder cancer diagnosis by finding out some urinary nucleosides with good discriminative performance for bladder cancer recognition in urinary nucleoside profile.
  • METHODS: 20 urinary samples for cancer and the same number for control are collected and treated by capillary electrophoresis-mass spectrometry experiments to achieve urinary nucleoside profile, in which 44 peaks were integrated and the ratios of the relative peak area to the concentration of urinary creatinine were used as features to describe all samples.
  • Support vector machine based recursive feature elimination (SVM-RFE) and a new feature selection method called support vector machine based partial exhaustive search algorithm (SVM-PESA) were used for biomarker identification and seeking optimal feature subsets for bladder cancer recognition.
  • By analyzing the statistical histogram of features' appearance frequency in several best feature subsets, urinary nucleosides with m/z 317, 290 and 304 were thought as potential biomarkers for bladder cancer recognition.
  • CONCLUSIONS: These results indicated urinary nucleosides may be useful as tumor biomarkers for bladder cancer, and the new method for biomarker selection is effective.
  • [MeSH-major] Biomarkers, Tumor / urine. Chemistry, Clinical / methods. Nucleosides / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693304.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nucleosides
  •  go-up   go-down


43. Kumaraguruparan R, Balachandran C, Manohar BM, Nagini S: Altered oxidant-antioxidant profile in canine mammary tumours. Vet Res Commun; 2005 May;29(4):287-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxidative stress arising due to overproduction of reactive oxygen species, coupled with altered antioxidant capacities has been implicated in the pathogenesis of all types of cancers.
  • Lipid peroxidation as evidenced by the formation of thiobarbituric acid-reactive substances, lipid hydroperoxides, and conjugated dienes, as well as the status of the antioxidants superoxide dismutase, catalase, reduced glutathione, glutathione peroxidase, glutathione S-transferase and vitamin C, in tumour tissues of 25 bitches was estimated.
  • Lipid peroxidation in tumour tissues was enhanced compared to the corresponding adjacent uninvolved tissues.
  • This was accompanied by significant elevation in both enzymatic and non-enzymatic antioxidants.
  • This study suggests that upregulation of antioxidants induced by lipid peroxidation confers a selective growth advantage to tumour cells over their adjacent normal counterparts.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutagenesis. 1998 May;13(3):287-305 [9643589.001]
  • [Cites] J Vet Med Sci. 1999 Jan;61(1):27-32 [10027159.001]
  • [Cites] Cancer Res. 1974 Nov;34(11):2859-68 [4529096.001]
  • [Cites] AACN Clin Issues. 2002 Nov;13(4):540-9 [12473916.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7 Suppl 1:S17-23 [10866031.001]
  • [Cites] J Vet Med Sci. 2001 Oct;63(10):1103-8 [11714026.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4 [14641084.001]
  • [Cites] Cancer Lett. 1997 Oct 28;119(1):13-9 [18372516.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(2):173-82 [12038708.001]
  • [Cites] Clin Chim Acta. 2002 Nov;325(1-2):165-70 [12367782.001]
  • [Cites] J Cell Physiol. 1995 Jun;163(3):555-60 [7539813.001]
  • [Cites] Science. 1973 Feb 9;179(4073):588-90 [4686466.001]
  • [Cites] Toxicol Lett. 1995 Dec;82-83:395-8 [8597083.001]
  • [Cites] J Comp Pathol. 2003 May;128(4):260-8 [12834609.001]
  • [Cites] J Small Anim Pract. 2000 Jul;41(7):287-91 [10976622.001]
  • [Cites] Clin Biochem. 2000 Jun;33(4):279-84 [10936586.001]
  • [Cites] Monaldi Arch Chest Dis. 2001 Apr;56(2):110-4 [11499296.001]
  • [Cites] Hum Gene Ther. 1997 Mar 20;8(5):585-95 [9095410.001]
  • [Cites] Biochemistry. 1995 Mar 14;34(10):3325-37 [7880828.001]
  • [Cites] J Toxicol Environ Health A. 2001 Oct 12;64(3):213-22 [11594700.001]
  • [Cites] Curr Opin Cell Biol. 1999 Dec;11(6):745-52 [10600713.001]
  • [Cites] J Biol Chem. 1974 Nov 25;249(22):7130-9 [4436300.001]
  • [Cites] J Biol Chem. 1982 Dec 25;257(24):14937-43 [6816802.001]
  • [Cites] Indian J Biochem Biophys. 1984 Apr;21(2):130-2 [6490072.001]
  • [Cites] Natl Med J India. 2000 Nov-Dec;13(6):304-10 [11209486.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):833-9 [9635871.001]
  • [Cites] Clin Biochem. 2000 Nov;33(8):657-62 [11166013.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 2003 May;33(3):573-96 [12852237.001]
  • [Cites] Exp Mol Pathol. 1968 Oct;9(2):271-8 [4952076.001]
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):87-95 [10766427.001]
  • [Cites] FASEB J. 1999 Jul;13(10):1169-83 [10385608.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1468-74 [9108447.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):389-94 [4556490.001]
  • [Cites] Med Sci Monit. 2002 Apr;8(4):RA79-92 [11951081.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Biochem Mol Toxicol. 2001;15(6):296-9 [11835628.001]
  • [Cites] Biochem J. 1997 Jul 1;325 ( Pt 1):183-9 [9224645.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 1;89(1):40-8 [8978405.001]
  • [Cites] Indian J Exp Biol. 2002 Nov;40(11):1213-32 [13677623.001]
  • [Cites] Mol Pharmacol. 2001 Sep;60(3):488-96 [11502879.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):205-9 [9180231.001]
  • (PMID = 15751580.001).
  • [ISSN] 0165-7380
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Oxidants
  •  go-up   go-down


44. Staudacher C, Vignali A: Laparoscopic surgery for rectal cancer: The state of the art. World J Gastrointest Surg; 2010 Sep 27;2(9):275-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for rectal cancer: The state of the art.
  • At present time, there is evidence from randomized controlled studies of the success of laparoscopic resection for the treatment of colon cancer with reported smaller incisions, lower morbidity rate and earlier recovery compared to open surgery.
  • Technical limitations and a steep learning curve have limited the wide application of mini-invasive surgery for rectal cancer.
  • The present article discusses the current status of laparoscopic resection for rectal cancer.
  • A review of the more recent retrospective, prospective and randomized controlled trial (RCT) data on laparoscopic resection of rectal cancer including the role of trans-anal endoscopic microsurgery and robotics was performed.
  • A particular emphasis was dedicated to mid and low rectal cancers.
  • Few prospective and RCT trials specifically addressing laparoscopic rectal cancer resection are currently available in the literature.
  • Concerns have recently been raised in the largest RCT trial of the oncological adequacy of laparoscopy in terms of increased rate of circumferential margin.
  • On the basis of available data in the literature, the mini-invasive approach to rectal cancer surgery has some short-term advantages and does not seem to confer any disadvantage in term of local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160896.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999691
  • [Keywords] NOTNLM ; Laparoscopy / Long-term outcome / Postoperative complications / Prognosis / Rectal cancer / Recurrence rate / Robotics / Transanal endoscopic microsurgery
  •  go-up   go-down


45. Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, Zhang S, Gao ZF: Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol; 2005 May 14;11(18):2704-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.
  • AIM: To produce high-quality polyclonal antibody to lysosome-associated protein transmembrane 4B-35 and to identify LAPTM4B-35 expression in cancer tissues and its correlation with differentiation status of hepatocellular carcinoma (HCC).
  • The expression of LAPTM4B-35 in HCC and other six cancer tissues was investigated via tissue chip and immunohistochemical analysis.
  • LAPTM4B-35 was remarkably expressed in several cancers, such as HCC, breast cancer, gastric carcinoma, lung cancer, and colon carcinoma, but not commonly expressed in esophageal cancer and rectum carcinoma.
  • It identified the expression of LAPTM4B-35 in some cancer tissues originated from single layer cuboidal and columnar epithelial cells and firmly demonstrated that the expression of LAPTM4B-35 in HCC was inversely correlated with the differentiation of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Membrane Proteins / chemistry. Membrane Proteins / metabolism. Neoplasms / metabolism. Oncogene Proteins / chemistry. Oncogene Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15884107.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / LAPTM4B protein, human; 0 / Membrane Proteins; 0 / Oncogene Proteins
  • [Other-IDs] NLM/ PMC4305901
  •  go-up   go-down


46. Saranovic D, Barisic G, Krivokapic Z, Masulovic D, Djuric-Stefanovic A: Endoanal ultrasound evaluation of anorectal diseases and disorders: technique, indications, results and limitations. Eur J Radiol; 2007 Mar;61(3):480-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT and conventional barium studies offer limited information in local staging of rectal and perirectal neoplasms, anal carcinomas and extension perianal fistulas in patients with inflamamatory bowel disease, or in evaluating patients with fecal incontinence.
  • During past decade, sonography and MR imaging have resulted in significant improvement in the imaging of rectal and perirectal and anal and perianal disease.
  • The aim of this article is to review possibility of the EAUS in the evaluation both normal anal anatomy and anorectal disease and disorders (anal carcinoma, sphincter defects, anal fistulas, perianal abscesses and other pathological conditions).
  • [MeSH-major] Anal Canal / ultrasonography. Anus Diseases / ultrasonography. Endosonography. Rectal Diseases / ultrasonography. Rectum / ultrasonography

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188828.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 37
  •  go-up   go-down


47. Doornebosch PG, Ferenschild FT, de Wilt JH, Dawson I, Tetteroo GW, de Graaf EJ: Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer. Dis Colon Rectum; 2010 Sep;53(9):1234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer.
  • PURPOSE: The aim of this study was to evaluate the management and outcome of local recurrences after transanal endoscopic microsurgery for T1 rectal cancer.
  • METHODS: Consecutive patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer at a Dutch referral center (IJsselland Hospital) were registered in a prospective database.
  • Follow-up was according to Dutch guidelines on rectal cancer, with additional rigid rectoscopy and endorectal ultrasound examinations every 3 months for the first 2 years, and every 6 months thereafter.
  • RESULTS: Of a total of 88 patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer, 18 patients (20.5%) had a local recurrence.
  • Median age at diagnosis of recurrence was 74 (range, 56-84) years.
  • In 15 patients (94%), a microscopically negative excision margin was obtained; in 1 patient, the excision margin was microscopically positive.
  • At 3 years, overall survival was 31%; cancer-related survival was 58%.
  • CONCLUSIONS: Recurrent disease after transanal endoscopic microsurgery for T1 rectal cancer is a major problem.
  • Tailoring selection of T1 rectal cancers and exploring possible adjuvant treatment strategies following salvage procedures should be the next steps toward improving survival.
  • [MeSH-major] Endoscopy, Gastrointestinal. Microsurgery / methods. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Anal Canal. Endosonography. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome


48. Cinti SK, Gandhi T, Riddell J 4th: Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier? AIDS Read; 2008 Jan;18(1):18-20, 26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier?
  • Non-AIDS-defining cancers have recently gained more attention, and it appears that several of these cancers may be more common the the HAART era.
  • By most accounts in the literature, the overall risk of non-AIDS-defining cancer in HIV-infected persons is 2 to 3 times that in the general population.
  • In this article, we review the literature on 5 of the most common non-AIDS-defining cancers (Hodgkin disease, anal cancer, hepatocellular carcinoma, oral cancer, and lung cancer) in the pre- and post-HAART periods.
  • It remains unclear whether earlier initiation (CD4+ cell count above 350/microL) of antiretroviral therapy may be beneficial in preventing non-AIDS-defining cancer.
  • [MeSH-minor] Anus Neoplasms / complications. Anus Neoplasms / epidemiology. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / epidemiology. Hodgkin Disease / complications. Hodgkin Disease / epidemiology. Humans. Liver Neoplasms / complications. Liver Neoplasms / epidemiology. Lung Neoplasms / complications. Lung Neoplasms / epidemiology. Mouth Neoplasms / complications. Mouth Neoplasms / epidemiology


49. Kirschner KN, Lexa KW, Salisburg AM, Alser KA, Joseph L, Andersen TT, Bennett JA, Jacobson HI, Shields GC: Computational design and experimental discovery of an antiestrogenic peptide derived from alpha-fetoprotein. J Am Chem Soc; 2007 May 16;129(19):6263-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is the most common cancer among women, and tamoxifen is the preferred drug for estrogen receptor-positive breast cancer treatment.
  • Many of these cancers are intrinsically resistant to tamoxifen or acquire resistance during treatment.
  • Consequently, there is an ongoing need for breast cancer drugs that have different molecular targets.
  • Previous work has shown that 8-mer and cyclic 9-mer peptides inhibit breast cancer in mouse and rat models, interacting with an unsolved receptor, while peptides smaller than eight amino acids did not.
  • These analogues were synthesized and shown to inhibit estrogen-dependent cell growth in a mouse uterine growth assay, a test showing reliable correlation with human breast cancer inhibition.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441722.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / F32 GM100619; United States / NCI NIH HHS / CA / R01 CA102540; United States / NCI NIH HHS / CA / R15 CA115524
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor Modulators; 0 / Oligopeptides; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ NIHMS424253; NLM/ PMC4272344
  •  go-up   go-down


50. Lieber CA, Majumder SK, Ellis DL, Billheimer DD, Mahadevan-Jansen A: In vivo nonmelanoma skin cancer diagnosis using Raman microspectroscopy. Lasers Surg Med; 2008 Sep;40(7):461-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo nonmelanoma skin cancer diagnosis using Raman microspectroscopy.
  • BACKGROUND AND OBJECTIVES: Nonmelanoma skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common skin cancers, presenting nearly as many cases as all other cancers combined.
  • The current gold-standard for clinical diagnosis of these lesions is histopathologic examination, an invasive, time-consuming procedure.
  • There is thus considerable interest in developing a real-time, automated, noninvasive tool for nonmelanoma skin cancer diagnosis.
  • In this study, we explored the capability of Raman microspectroscopy to provide differential diagnosis of BCC, SCC, inflamed scar tissue, and normal tissue in vivo.
  • Using this portable system, we measured Raman spectra of 21 suspected nonmelanoma skin cancers in 19 patients with matched normal skin spectra.
  • CONCLUSIONS: These findings reveal Raman microspectroscopy to be a viable tool for real-time diagnosis and guidance of nonmelanoma skin cancer resection.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):441-8 [10951281.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] J Invest Dermatol. 2002 Jul;119(1):64-9 [12164926.001]
  • [Cites] Biophys J. 2003 Jul;85(1):572-80 [12829511.001]
  • [Cites] Appl Spectrosc. 2003 Nov;57(11):1363-7 [14658149.001]
  • [Cites] BJU Int. 2004 Jun;93(9):1232-6 [15180613.001]
  • [Cites] Cytometry A. 2004 Jul;60(1):81-9 [15229860.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Feb;17(1):55-61 [7766269.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Feb;17(1):62-8 [7766270.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):393-8 [9540981.001]
  • [Cites] Biospectroscopy. 1998;4(5 Suppl):S31-9 [9787912.001]
  • [Cites] Prostate. 1999 Sep 15;41(1):12-9 [10440871.001]
  • [Cites] Biopolymers. 2005 Apr 5;77(5):264-72 [15657894.001]
  • [Cites] Appl Spectrosc. 2005 Apr;59(4):393-400 [15901323.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Appl Spectrosc. 2007 May;61(5):548-57 [17555625.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034004 [17614712.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):434-42 [11231318.001]
  • (PMID = 18727020.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095995-01A1; United States / NCI NIH HHS / CA / R21 CA095995; United States / NCI NIH HHS / CA / R21 CA095995-01A1; United States / NCI NIH HHS / CA / R21 CA95995
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS146135; NLM/ PMC2782422
  •  go-up   go-down


51. Sharma P, Kumar N, Bahadur AK, Shukla DK: Quantitative analysis of radiation-associated cellular changes in oral cancer and their correlations with histologic grade and clinical stage: a multivariate evaluation of 43 patients. Anal Quant Cytol Histol; 2005 Apr;27(2):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of radiation-associated cellular changes in oral cancer and their correlations with histologic grade and clinical stage: a multivariate evaluation of 43 patients.
  • OBJECTIVE: To quantitate radiation-associated cytologic abnormalities in oral cancer cells and analyze their relationships with radiation dose, clinical stage and histologic grade.
  • STUDY DESIGN: Forty-three oral cancer patients receiving 2 Gy of fractionated radiotherapy per day were enrolled.
  • Scrape smears were taken from the tumor surface before treatment and serially after 6-, 12-, 18- and 24-Gy fractions.
  • Counts were done after Giemsa staining for the number of tumor cells; micronucleated, nuclear budded, binucleated and multinucleated tumor cells; cells with abnormal nuclear chromatin and membrane; cells with cytoplasmic granulation and vacuolization; and histiocytic giant cells.
  • Most cytologic features were not significantly different in early and advanced clinical stage cancers before or after irradiation (Mann-Whitney U test).
  • Since micronucleation and nuclear budding remain significantly different between histologic grades even after 24 Gy of irradiation, they may be utilized as clinically practicable alternatives to biopsy at this stage and may be useful in further studies on cytologic prognostication of irradiated oral cancer.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913204.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF: Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol; 2006;1:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
  • PURPOSE: To investigate the outcome of HIV-seropositive patients under highly active antiretroviral treatment (HAART) with anal cancer treated with radiotherapy (RT) alone or in combination with standard chemotherapy (CT).
  • Pattern of care, local disease control (LC), overall survival (OS), cancer-specific survival (CSS), and toxicity were assessed.
  • CONCLUSION: Despite high response rates to organ preserving treatment with RT with or without CT, local tumor failure seems to be high in HIV-positive patients receiving HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Anus Neoplasms / virology. HIV Infections / complications. HIV Infections / drug therapy. Radiotherapy / methods


53. Heikkilä K, Ebrahim S, Lawlor DA: A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health; 2007 Sep;61(9):824-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review of the association between circulating concentrations of C reactive protein and cancer.
  • The objective of this study was to review and summarise the published evidence for an association between circulating concentrations of C reactive protein (CRP) and cancer through a systematic review.
  • In most prevalent studies, CRP concentrations were found to be higher in patients with cancer than in healthy controls or controls with benign conditions.
  • Of the nine large prospective studies identified in this review, four reported no relationship between circulating CRP levels and breast, prostate or colorectal cancers, and five studies found that CRP was associated with colorectal or lung cancers.
  • Most of the studies evaluating CRP as a diagnostic marker of cancer did not present relevant statistical analyses.
  • The prospective studies provided no strong evidence for a causal role of CRP in cancer.
  • Instead of further prevalent studies, more large prospective studies and CRP gene-cancer association studies would be valuable in investigating the role of CRP in cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2004 Mar;28(3):259-66 [14687621.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):84-91 [11857390.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 May;21(5):557-62 [4007021.001]
  • [Cites] Eur Urol. 2001 Feb;39(2):215-21 [11223683.001]
  • [Cites] Zentralbl Neurochir. 1990;51(3):129-37 [2092546.001]
  • [Cites] J Asthma. 2003;40(7):733-9 [14626329.001]
  • [Cites] Respir Med. 2002 Aug;96(8):553-8 [12195834.001]
  • [Cites] QJM. 2004 Mar;97(3):163-6 [14976273.001]
  • [Cites] Cancer Detect Prev. 1983;6(1-2):221-5 [6603907.001]
  • [Cites] Respir Med. 1998 Jan;92(1):76-83 [9519229.001]
  • [Cites] Stat Med. 1992 May;11(7):953-61 [1604073.001]
  • [Cites] Cas Lek Cesk. 2000 Apr 12;139(7):208-12 [10916207.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):21-5 [12764738.001]
  • [Cites] Arch Gynecol Obstet. 1992;251(2):69-78 [1374604.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):257-63 [15944798.001]
  • [Cites] Am J Hematol. 2003 Apr;72(4):229-33 [12666132.001]
  • [Cites] Blood. 2005 Jul 1;106(1):362-7 [15774616.001]
  • [Cites] Cancer Immunol Immunother. 1991;33(6):403-10 [1878893.001]
  • [Cites] Prostate. 2004 Jun 1;59(4):393-400 [15065087.001]
  • [Cites] Dig Dis Sci. 2000 Mar;45(3):500-8 [10749324.001]
  • [Cites] Am J Hematol. 2003 Dec;74(4):231-7 [14635202.001]
  • [Cites] Am J Hematol. 2004 Feb;75(2):101-6 [14755377.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):220-7 [10228796.001]
  • [Cites] Med Wieku Rozwoj. 2004 Oct-Dec;8(4 Pt 2):1081-9 [15951603.001]
  • [Cites] Int J Cancer. 1985 Jul 15;36(1):49-54 [4018905.001]
  • [Cites] Int J Oncol. 1999 Oct;15(4):823-7 [10493968.001]
  • [Cites] Lancet. 2005 Dec 3;366(9501):1954-9 [16325697.001]
  • [Cites] World J Gastroenterol. 2005 Mar 21;11(11):1639-43 [15786541.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):881-6 [12239630.001]
  • [Cites] Int J Biol Markers. 2004 Jan-Mar;19(1):52-7 [15077927.001]
  • [Cites] Cytokine. 2004 Jul 21-Aug 7;27(2-3):90-2 [15242698.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):704-7 [16513341.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2483-7 [16489056.001]
  • [Cites] Clin Sci (Lond). 1999 Jan;96(1):83-7 [9857110.001]
  • [Cites] J Gastroenterol. 1996 Aug;31(4):538-45 [8844475.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Prev Med. 2005 Aug;41(2):651-6 [15917065.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):119-24 [668189.001]
  • [Cites] Cancer Res. 1979 Feb;39(2 Pt 1):542-4 [83910.001]
  • [Cites] Oncol Rep. 1995 Mar;2(2):215-9 [21597715.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1004-9 [7842401.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):585-90 [14762037.001]
  • [Cites] Nutr Cancer. 2002;44(2):157-60 [12734062.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 May;25(5):1051-6 [15731495.001]
  • [Cites] Med Oncol. 2005;22(4):353-8 [16260852.001]
  • [Cites] Ann Intern Med. 2005 Mar 15;142(6):425-32 [15767620.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1993-5 [15570310.001]
  • [Cites] Ann Intern Med. 2002 Apr 2;136(7):529-33 [11926788.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):89-95 [12637157.001]
  • [Cites] World J Gastroenterol. 2005 Dec 7;11(45):7174-8 [16437667.001]
  • [Cites] World J Surg. 2003 Jul;27(7):761-4 [14509501.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):755-64 [16114015.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(4):229-32 [7507117.001]
  • [Cites] J Clin Pathol. 2004 Aug;57(8):856-60 [15280408.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(3):159-62 [7544987.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1755-7 [15505624.001]
  • [Cites] Ann Hematol. 2003 Jan;82(1):19-23 [12574959.001]
  • [Cites] Anal Chem. 2005 Sep 15;77(18):5990-7 [16159132.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:1-13 [15915584.001]
  • [Cites] BJU Int. 2005 May;95(7):961-2 [15839913.001]
  • [Cites] Support Care Cancer. 2001 Mar;9(2):124-8 [11305070.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1369-79 [10389921.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11193-202 [16322270.001]
  • [Cites] Respirology. 2004 Mar;9(1):66-9 [14982604.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1095-8 [7734307.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1289-93 [12168939.001]
  • [Cites] Br J Cancer. 1993 Dec;68(6):1195-8 [8260373.001]
  • [Cites] Int J Cancer. 1984 Jun 15;33(6):771-5 [6735523.001]
  • [Cites] Pathol Biol (Paris). 1991 Oct;39(8):769-73 [1722302.001]
  • [Cites] Cytokine. 2002 Jul 7;19(1):21-6 [12200109.001]
  • [Cites] Blood Coagul Fibrinolysis. 2002 Mar;13(2):165-8 [11914659.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):301-7 [11144523.001]
  • [Cites] Arch Gynakol. 1972;213(1):54-72 [4629806.001]
  • [Cites] Med Pediatr Oncol. 1984;12(1):68-72 [6199656.001]
  • [Cites] Ann Surg. 1991 Jan;213(1):26-31 [1898691.001]
  • [Cites] Am J Reprod Immunol. 1983 Jul-Aug;4(1):11-20 [6194700.001]
  • [Cites] Surg Oncol. 2002 May;10(4):153-69 [12020670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):381-4 [16492932.001]
  • [Cites] Kidney Int. 2005 Nov;68(5):2103-10 [16221209.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):132-8 [10520033.001]
  • [Cites] Clin Nutr. 2002 Apr;21(2):161-4 [12056790.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Eur J Cancer. 2000 May;36(7):889-94 [10785594.001]
  • [Cites] Blood. 1996 Jan 15;87(2):712-6 [8555495.001]
  • [Cites] J Natl Med Assoc. 2005 Feb;97(2):276-80 [15712792.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1051-3 [16106418.001]
  • [Cites] J Lab Clin Med. 2006 Apr;147(4):174-81 [16581345.001]
  • [Cites] Neoplasma. 1999;46(3):141-9 [10613588.001]
  • [Cites] Dis Esophagus. 2005;18(3):146-50 [16045574.001]
  • [Cites] Circulation. 2004 Jun 22;109(24):3022-8 [15184288.001]
  • [Cites] Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):161-6 [15314978.001]
  • [Cites] Eur J Med. 1992 Jul-Aug;1(4):201-7 [1341445.001]
  • [Cites] Mediators Inflamm. 2005 Aug 14;2005(3):171-4 [16106104.001]
  • [Cites] Eur J Gynaecol Oncol. 1991;12(5):375-83 [1717278.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):701-6 [15010071.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):377-82 [15558809.001]
  • [Cites] Thromb Haemost. 2005 May;93(5):955-63 [15886815.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):690-5 [16614110.001]
  • [Cites] Oncology. 1981;38(5):286-91 [6115350.001]
  • [Cites] Lung Cancer. 2001 Jun;32(3):307-12 [11390012.001]
  • [Cites] BMJ. 2005 May 7;330(7499):1076-9 [15879400.001]
  • [Cites] Int J Biol Markers. 1993 Jan-Mar;8(1):14-20 [8496627.001]
  • [Cites] Nutr Cancer. 1997;28(3):308-12 [9343841.001]
  • [Cites] World J Surg. 2002 Nov;26(11):1328-32 [12297927.001]
  • [Cites] World J Gastroenterol. 2004 Apr 15;10(8):1115-20 [15069709.001]
  • [Cites] Clin Lab Haematol. 2003 Feb;25(1):41-6 [12542441.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):248-52 [9648596.001]
  • [Cites] BMC Cancer. 2005;5:110 [16117833.001]
  • [Cites] Nutrition. 2000 Jun;16(6):425-8 [10869897.001]
  • [Cites] Asian Pac J Allergy Immunol. 1988 Jun;6(1):7-10 [3166645.001]
  • [Cites] J Formos Med Assoc. 1999 Feb;98(2):85-91 [10083762.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2063-9 [12842840.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8 [16214925.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):433-9 [15489136.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S185-9 [16127232.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):135-40 [12714883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9 [11504947.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Apr;15(4):417-21 [10824887.001]
  • [Cites] J Lab Clin Med. 2004 Oct;144(4):176-82 [15514585.001]
  • [Cites] Acta Haematol. 1994;92(1):1-7 [7985475.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):723-33 [12072041.001]
  • [Cites] Am J Clin Nutr. 1997 Nov;66(5):1283-5 [9356549.001]
  • [Cites] J Mol Med (Berl). 2003 Oct;81(10):664-73 [12928788.001]
  • [Cites] Ann Clin Res. 1988;20(6):414-6 [3218913.001]
  • [Cites] Int J Epidemiol. 2003 Feb;32(1):1-22 [12689998.001]
  • (PMID = 17699539.001).
  • [ISSN] 0143-005X
  • [Journal-full-title] Journal of epidemiology and community health
  • [ISO-abbreviation] J Epidemiol Community Health
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600705
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  • [Number-of-references] 127
  • [Other-IDs] NLM/ PMC2703800
  •  go-up   go-down


54. Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF: A mouse model for human anal cancer. Cancer Prev Res (Phila); 2010 Dec;3(12):1534-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model for human anal cancer.
  • Human anal cancers are associated with high-risk human papillomaviruses (HPV) that cause other anogenital cancers and head and neck cancers.
  • As with other cancers, HPV16 is the most common high-risk HPV in anal cancers.
  • We describe the generation and characterization of a mouse model for human anal cancer.
  • This model makes use of K14E6 and K14E7 transgenic mice in which the HPV16 E6 and E7 genes are directed in their expression to stratified squamous epithelia.
  • HPV16 E6 and E7 possess oncogenic properties including, but not limited to, their capacity to inactivate the cellular tumor suppressors p53 and pRb, respectively.
  • Both E6 and E7 were found to be functionally expressed in the anal epithelia of K14E6/K14E7 transgenic mice.
  • To assess the susceptibility of these mice to anal cancer, mice were treated topically with dimethylbenz[a]anthracene (DMBA), a chemical carcinogen that is known to induce squamous cell carcinomas in other sites.
  • Histopathologic analyses confirmed that the HPV16 transgenic mice were increased in their susceptibility to anal cancers and precancerous lesions.
  • Biomarker analyses demonstrated that these mouse anal cancers exhibit properties that are similar to those observed in HPV-positive precursors to human anal cancer.
  • This is the first mouse model for investigating the contributions of viral and cellular factors in anal carcinogenesis, and should provide a platform for assessing new therapeutic modalities for treating and/or preventing this type of cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3519-25 [6286109.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1626-35 [17308103.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4605-19 [17510386.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6106-12 [17616666.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2668-73 [17721920.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] Mol Cancer. 2008;7:3 [18184435.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):144-50 [19838162.001]
  • [Cites] J Am Acad Dermatol. 2010 Sep;63(3):490-8 [20006407.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Virology. 2000 Feb 15;267(2):141-50 [10662610.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • (PMID = 20947489.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098428-08; United States / NCI NIH HHS / CA / P01 CA022443-330006; United States / NCI NIH HHS / CA / R01 CA098428-09; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / P01 CA022443-320006; United States / NCI NIH HHS / CA / CA098428-08; United States / NCI NIH HHS / CA / CA022443-330006; United States / NCI NIH HHS / CA / CA141583-02; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / CA022443-320006; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / CI T32 CA090217; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ NIHMS211621; NLM/ PMC3006089
  •  go-up   go-down


55. Glynne-Jones R, Mawdsley S: Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe? Nat Clin Pract Oncol; 2008 Dec;5(12):692-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe?
  • This Practice Point commentary discusses the findings of the Intergroup RTOG 98-11 trial, which aimed to investigate both the potential role of cisplatin as neoadjuvant chemotherapy, and also its role concurrently in combination with radiotherapy, for anal-canal carcinoma.
  • Although chemoradiotherapy has had an important effect on the treatment of anal cancer, and allows preservation of anorectal function with survival rates similar to or better than those of surgical treatment, overall survival rates for advanced tumors are still in the region of 50-60% at 5 years.
  • A strong theoretical rationale for cisplatin-based treatment in anal cancer exists; several phase II trials have demonstrated a high response rate with reduced colostomy rates.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852720.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikström P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One; 2010;5(12):e14175
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.
  • BACKGROUND: Metastasis to the bone is one clinically important features of prostate cancer (PCa).
  • METHODOLOGY/PRINCIPAL FINDINGS: Metabolomics was applied for the study of PCa bone metastases (n = 20) in comparison with corresponding normal bone (n = 14), and furthermore of malignant (n = 13) and benign (n = 17) prostate tissue and corresponding plasma samples obtained from patients with (n = 15) and without (n = 13) diagnosed metastases and from men with benign prostate disease (n = 30).
  • Results were verified in a separate test set including metastatic and normal bone tissue from patients with other cancers (n = 7).
  • Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone.
  • Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.
  • Immunohistochemical staining of PCa bone metastases showed intense staining of the low density lipoprotein receptor and variable levels of the scavenger receptor class B type 1 and 3-hydroxy-3-methylglutaryl-coenzyme reductase in tumor epithelial cells, indicating possibilities for influx and de novo synthesis of cholesterol.
  • [MeSH-minor] Biopsy. Bone and Bones / pathology. Computational Biology / methods. Gas Chromatography-Mass Spectrometry / methods. Humans. Immunohistochemistry / methods. Male. Neoplasm Metastasis. Prostatic Neoplasms / pathology. Sarcosine / metabolism. Tissue Distribution

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2001 Dec;10(6):507-13 [11916349.001]
  • [Cites] PLoS One. 2009;4(9):e7075 [19763266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32 [14512514.001]
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):39-77 [14592533.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1150-60 [15130918.001]
  • [Cites] Prog Clin Biol Res. 1981;75A:279-324 [6175978.001]
  • [Cites] Science. 1986 Apr 4;232(4746):34-47 [3513311.001]
  • [Cites] Prostate. 1992;20(2):151-8 [1549552.001]
  • [Cites] Magn Reson Med. 1992 May;25(1):140-7 [1375702.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):149-57 [8429778.001]
  • [Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1429-34 [9673351.001]
  • [Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5635-42 [16131076.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):8086-94 [16351159.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1407-14 [16739992.001]
  • [Cites] Urology. 2006 Jun;67(6):1205-11 [16765180.001]
  • [Cites] Curr Treat Options Oncol. 2006 Sep;7(5):355-62 [16904052.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2265-77 [16455816.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] J Urol. 2007 Dec;178(6):2252-9 [17936845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7 [17971518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Pharmacol Sci. 2008 Apr;106(4):536-41 [18431036.001]
  • [Cites] Trends Endocrinol Metab. 2008 May-Jun;19(4):113-21 [18356074.001]
  • [Cites] J Urol. 2008 Jun;179(6):2422-6 [18433783.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Mol Cancer. 2008;7:72 [18799019.001]
  • [Cites] Cancer Biomark. 2008;4(4-5):263-76 [18957715.001]
  • [Cites] Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20 [18782595.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1259-66 [18704722.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):352-61 [19063642.001]
  • [Cites] Cancer Treat Rev. 2009 Feb;35(1):1-8 [18778896.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):1017-26 [19179610.001]
  • [Cites] Cancer. 2009 Jul 1;115(13 Suppl):3058-67 [19544547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13 [19887582.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):781-7 [19526315.001]
  • [Cites] Endocr Relat Cancer. 2010 Dec;17(4):885-95 [20688881.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2227-31 [11956073.001]
  • (PMID = 21151972.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol; Z711V88R5F / Sarcosine
  • [Other-IDs] NLM/ PMC2997052
  •  go-up   go-down


57. Rowe LA, Degtyareva N, Doetsch PW: DNA damage-induced reactive oxygen species (ROS) stress response in Saccharomyces cerevisiae. Free Radic Biol Med; 2008 Oct 15;45(8):1167-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At high levels, ROS can lead to impaired physiological function through cellular damage of DNA, proteins, lipids, and other macromolecules, which can lead to certain human pathologies including cancers, neurodegenerative disorders, and cardiovascular disease, as well as aging.
  • We find that when DNA damage is introduced into cells from exogenous or endogenous sources there is an increase in the amount of intracellular ROS which is not directly related to cell death.

  • COS Scholar Universe. author profiles.
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):240-6 [9069263.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):30-8 [8695238.001]
  • [Cites] J Immunol Methods. 1997 Mar 28;202(2):133-41 [9107302.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1710-20 [9130715.001]
  • [Cites] J Cell Biol. 1997 Nov 3;139(3):729-34 [9348289.001]
  • [Cites] Anal Biochem. 1997 Nov 15;253(2):162-8 [9367498.001]
  • [Cites] Nitric Oxide. 1997 Apr;1(2):145-57 [9701053.001]
  • [Cites] Genes Cells. 1998 Aug;3(8):521-32 [9797454.001]
  • [Cites] Free Radic Biol Med. 1998 Nov 1;25(7):826-31 [9823548.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7416-29 [9857197.001]
  • [Cites] Yeast. 1998 Dec;14(16):1511-27 [9885153.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2929-35 [10082560.001]
  • [Cites] Cell Signal. 1999 Jan;11(1):1-14 [10206339.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):13-27 [15603750.001]
  • [Cites] Gene. 2005 Jan 3;344:43-51 [15656971.001]
  • [Cites] Trends Cell Biol. 2005 Jun;15(6):319-26 [15953550.001]
  • [Cites] Annu Rev Microbiol. 2005;59:357-77 [16153173.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Apoptosis. 2007 May;12(5):1011-23 [17453165.001]
  • [Cites] Cell Signal. 2007 Sep;19(9):1807-19 [17570640.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):813-24 [17848967.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Feb 4;243(1):13-9 [9473471.001]
  • [Cites] Oncogene. 1999 Nov 1;18(45):6104-11 [10557101.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8302-13 [10567555.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1897-905 [10583946.001]
  • [Cites] Mutat Res. 2000 Jun 30;451(1-2):39-51 [10915864.001]
  • [Cites] EMBO J. 2000 Oct 2;19(19):5157-66 [11013218.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):239-47 [11089981.001]
  • [Cites] Redox Rep. 2000;5(5):277-85 [11145102.001]
  • [Cites] Apoptosis. 2000 Nov;5(5):415-8 [11256882.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):11-7 [11753072.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):47-95 [11773609.001]
  • [Cites] Curr Genet. 2002 Jul;41(4):208-16 [12172961.001]
  • [Cites] Cell. 2002 Nov 15;111(4):471-81 [12437921.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Dec;66(4):630-70, table of contents [12456786.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3170-5 [12419811.001]
  • [Cites] Mutat Res. 2003 Nov 27;532(1-2):227-43 [14643439.001]
  • [Cites] Biochimie. 2003 Nov;85(11):1083-99 [14726015.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):181-9 [15039755.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22585-94 [15020594.001]
  • [Cites] FEBS Lett. 2004 Jun 1;567(1):80-5 [15165897.001]
  • [Cites] Nucleic Acids Res. 2004;32(12):3712-23 [15254273.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1123-32 [15279801.001]
  • [Cites] Annu Rev Plant Biol. 2004;55:373-99 [15377225.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Nov;78(11):7124-8 [6947277.001]
  • [Cites] Genes Dev. 1989 Mar;3(3):283-92 [2542125.001]
  • [Cites] Genetics. 1989 May;122(1):19-27 [2659436.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11632-9 [1646813.001]
  • [Cites] Arch Biochem Biophys. 1993 May;302(2):348-55 [8387741.001]
  • [Cites] J Leukoc Biol. 1994 Feb;55(2):253-8 [8301222.001]
  • [Cites] EMBO J. 1994 Feb 1;13(3):655-64 [8313910.001]
  • [Cites] Hypertension. 1995 Feb;25(2):155-61 [7843763.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8370-9 [9079661.001]
  • (PMID = 18708137.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P01 ES011163; United States / NIEHS NIH HHS / ES / P01 ES011163-06A1; United States / NIEHS NIH HHS / ES / ES 011163
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / Saccharomyces cerevisiae Proteins; 0 / Transcription Factors; 0 / YAP1 protein, S cerevisiae
  • [Other-IDs] NLM/ NIHMS74785; NLM/ PMC2643028
  •  go-up   go-down


58. Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF: Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol; 2009 Sep;175(3):1255-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone metastasis is a hallmark of advanced prostate and breast cancers, yet the critical factors behind attraction of tumors to the skeleton have not been validated.
  • The coincident up-regulation of SPARC and cathepsin K occurred both in vivo in experimental prostate bone tumors, and in vitro in co-cultures of bone marrow stromal cells with PC3 prostate carcinoma cells.
  • PC3-bone marrow stromal cell interaction increased secretion and processing of SPARC, as did co-cultures of bone marrow stromal cells with two other cancer cell lines.
  • In addition, bone marrow stromal cells that were either deficient in cathepsin K or treated with cathepsin K inhibitors had significantly reduced secretion and cleavage of SPARC.
  • Increases in secretion of pro-inflammatory cytokines (ie, interleukin-6, -8) coincident with overexpression of cathepsin K suggest possible mechanisms by which this enzyme contributes to tumor progression in the bone.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):407-11 [17826661.001]
  • [Cites] Gene. 2007 Nov 15;403(1-2):151-8 [17897792.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9894-902 [17942921.001]
  • [Cites] Cancer Biol Ther. 2007 Apr;6(4):618-9 [18027438.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):41-55 [18071636.001]
  • [Cites] Science. 2008 Feb 1;319(5863):624-7 [18239127.001]
  • [Cites] Nutr Rev. 2007 Dec;65(12 Pt 2):S147-51 [18240539.001]
  • [Cites] Biochimie. 2008 Feb;90(2):208-26 [17935853.001]
  • [Cites] Biomed Pharmacother. 2008 Feb;62(2):130-5 [17728092.001]
  • [Cites] Autoimmunity. 2008 Apr;41(3):183-94 [18365831.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):85-95 [18082147.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1185-98 [18243768.001]
  • [Cites] J Cell Biochem. 2008 Jun 1;104(3):721-32 [18253934.001]
  • [Cites] Cancer Metastasis Rev. 2008 Sep;27(3):523-37 [18459035.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5357-67 [18765527.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):9050-9 [18974151.001]
  • [Cites] Drug Resist Updat. 2008 Dec;11(6):231-46 [18849185.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Med Oncol. 2009;26(1):10-5 [18461289.001]
  • [Cites] J Cell Biochem. 2009 Mar 1;106(4):563-9 [19170075.001]
  • [Cites] J Rheumatol. 1998 Oct;25(10):1887-94 [9779840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13453-8 [9811821.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):32347-52 [9822715.001]
  • [Cites] J Clin Invest. 1999 Mar;103(5):731-8 [10074491.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1987-93 [10213511.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):791-9 [10229398.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1588-93 [10446855.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4453-7 [10485497.001]
  • [Cites] Bone. 2005 Jan;36(1):159-72 [15664014.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1727-36 [15637291.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):207-23 [15799821.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5123-32 [15958556.001]
  • [Cites] J Biol Chem. 2005 Aug 5;280(31):28370-81 [15929988.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7370-7 [16103089.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Dec;31(12):1363-6 [10641790.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):858-64 [10732759.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1140-9 [10741745.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2) [10881018.001]
  • [Cites] J Exp Med. 2000 Sep 18;192(6):789-99 [10993910.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):532-7 [11212246.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] J Bone Miner Res. 2001 Aug;16(8):1444-52 [11499867.001]
  • [Cites] J Bone Miner Res. 2001 Aug;16(8):1486-95 [11499871.001]
  • [Cites] Mol Carcinog. 2001 Oct;32(2):84-91 [11746820.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):17-25 [11773278.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] J Cell Physiol. 2003 Jan;194(1):71-9 [12447991.001]
  • [Cites] J Bone Miner Res. 2003 Feb;18(2):222-30 [12568399.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37849-57 [12867428.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):39044-50 [12885781.001]
  • [Cites] Histochem Cell Biol. 2003 Nov;120(5):391-400 [14600836.001]
  • [Cites] Histol Histopathol. 2004 Jan;19(1):189-99 [14702187.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Anal Biochem. 1983 Jun;131(2):538-47 [6193739.001]
  • [Cites] J Cell Biol. 1994 May;125(4):929-43 [7514608.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1012-8 [8083342.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12517-24 [8647860.001]
  • [Cites] Science. 1996 Aug 30;273(5279):1236-8 [8703060.001]
  • [Cites] Oncol Res. 1996;8(2):63-7 [8859776.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9237-43 [9083057.001]
  • [Cites] Genomics. 1997 Apr 15;41(2):169-76 [9143491.001]
  • [Cites] J Cell Physiol. 1997 Dec;173(3):327-34 [9369945.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5386-90 [9393764.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1395-9 [9537238.001]
  • [Cites] Biochem J. 1998 May 1;331 ( Pt 3):727-32 [9560298.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2209-16 [9605768.001]
  • [Cites] Anal Chem. 2005 Nov 1;77(21):6765-71 [16255572.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Bioorg Med Chem Lett. 2006 Apr 1;16(7):1985-9 [16413777.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5825-32 [16670288.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):847-54 [16690483.001]
  • [Cites] Nat Med. 2006 Jun;12(6):657-64 [16715089.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7968-75 [16912171.001]
  • [Cites] Prostate. 2006 Sep 1;66(12):1311-8 [16705739.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):764-75 [16990854.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s [17062703.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3646-53 [17440076.001]
  • [Cites] Clin Sci (Lond). 2007 Jun;112(11):567-75 [17241109.001]
  • [Cites] Neurosci Lett. 2007 May 29;419(2):172-7 [17490812.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):701-3 [17635127.001]
  • (PMID = 19700761.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056586; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / R01 CA 56586; United States / NCI NIH HHS / CA / P30 CA 22453; United States / NIEHS NIH HHS / ES / P30 ES 06639; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Interleukin-8; 0 / Osteonectin; EC 3.4.22.38 / Cathepsin K
  • [Other-IDs] NLM/ PMC2731144
  •  go-up   go-down


59. Shorter J: Emergence and natural selection of drug-resistant prions. Mol Biosyst; 2010 Jul;6(7):1115-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drug resistance is a refractory barrier in the battle against many fatal diseases caused by rapidly evolving agents, including HIV, apicomplexans and specific cancers.
  • Once in motion, this chain reaction of conformational replication can deplete all non-prion copies of a protein.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. QUINACRINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neural Transm (Vienna). 2006 Sep;113(9):1243-51 [16362635.001]
  • [Cites] Hum Mol Genet. 2006 Sep 15;15(18):2743-51 [16893904.001]
  • [Cites] Science. 2006 Sep 15;313(5793):1604-10 [16902091.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1781-4 [16990547.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Oct;50(10):3447-9 [17005828.001]
  • [Cites] Science. 2006 Oct 6;314(5796):133-6 [17023660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15806-11 [17038504.001]
  • [Cites] N Engl J Med. 2006 Nov 23;355(21):2254-5 [17124027.001]
  • [Cites] Lancet. 2006 Dec 9;368(9552):2061-7 [17161728.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19105-10 [17142317.001]
  • [Cites] J Mol Biol. 2007 Jan 19;365(3):773-82 [17097676.001]
  • [Cites] Adv Protein Chem. 2006;73:235-82 [17190616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19754-9 [17170131.001]
  • [Cites] Genes Dev. 2007 Jan 15;21(2):195-205 [17234885.001]
  • [Cites] Neuron. 2007 Feb 1;53(3):325-35 [17270731.001]
  • [Cites] Trends Mol Med. 2007 Feb;13(2):64-71 [17207661.001]
  • [Cites] FEBS J. 2007 Feb;274(3):588-605 [17288548.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2649-54 [17299036.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):668-71 [17410176.001]
  • [Cites] Science. 2007 May 4;316(5825):750-4 [17478722.001]
  • [Cites] Trends Biochem Sci. 2007 May;32(5):217-24 [17412596.001]
  • [Cites] PLoS Pathog. 2007 Mar;3(3):e31 [17352534.001]
  • [Cites] JAMA. 2007 May 23;297(20):2264-77 [17519416.001]
  • [Cites] Nature. 2007 May 24;447(7143):453-7 [17468747.001]
  • [Cites] Nature. 2007 May 31;447(7144):556-61 [17495929.001]
  • [Cites] EMBO J. 2007 Jul 11;26(13):3169-79 [17581637.001]
  • [Cites] Nature. 2007 Sep 13;449(7159):233-7 [17767153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17204-9 [17940007.001]
  • [Cites] Theor Popul Biol. 2007 Dec;72(4):560-75 [17915273.001]
  • [Cites] Science. 2007 Nov 9;318(5852):930-6 [17991853.001]
  • [Cites] Nat Neurosci. 2007 Dec;10(12):1587-93 [17965711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19023-8 [18024584.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1001-9 [18075579.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1059-71 [18083097.001]
  • [Cites] Neurosignals. 2008;16(1):63-74 [18097161.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1900-3 [18096801.001]
  • [Cites] Nat Rev Microbiol. 2008 Mar;6(3):187-98 [18246082.001]
  • [Cites] Science. 2008 Feb 15;319(5865):916-9 [18276881.001]
  • [Cites] Nat Chem Biol. 2008 Mar;4(3):197-9 [18223646.001]
  • [Cites] Nat Genet. 2008 Apr;40(4):460-5 [18362884.001]
  • [Cites] Nat Med. 2008 May;14(5):504-6 [18391962.001]
  • [Cites] Nat Med. 2008 May;14(5):501-3 [18391963.001]
  • [Cites] Neurology. 2008 May 13;70(20):1916-25 [18474848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 20;105(20):7159-64 [18480256.001]
  • [Cites] J Chem Inf Model. 2008 May;48(5):1055-73 [18505239.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):558-66 [18511942.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):544-6 [18523464.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10595-600 [18647832.001]
  • [Cites] Mol Biosyst. 2008 Sep;4(9):895-901 [18704227.001]
  • [Cites] Cell. 2008 Sep 5;134(5):769-81 [18775310.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13626-31 [18757733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13977-81 [18779569.001]
  • [Cites] J Neurochem. 2008 Oct;107(1):218-29 [18691383.001]
  • [Cites] EMBO J. 2008 Oct 22;27(20):2712-24 [18833196.001]
  • [Cites] J Am Chem Soc. 2008 Nov 12;130(45):14990-5001 [18937465.001]
  • [Cites] Exp Gerontol. 2008 Dec;43(12):1086-93 [18799131.001]
  • [Cites] Trends Genet. 2008 Dec;24(12):604-12 [18992957.001]
  • [Cites] PLoS Biol. 2008 Nov 25;6(11):e294 [19067491.001]
  • [Cites] Nat Cell Biol. 2008 Sep;10(9):1069-75 [19160487.001]
  • [Cites] Prion. 2007 Jan-Mar;1(1):48-52 [19164923.001]
  • [Cites] Prion. 2007 Apr-Jun;1(2):83-93 [19164918.001]
  • [Cites] Nat Cell Biol. 2009 Feb;11(2):219-25 [19151706.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2818-23 [19196973.001]
  • [Cites] Prion. 2008 Oct-Dec;2(4):135-40 [19242125.001]
  • [Cites] Nat Cell Biol. 2009 Mar;11(3):328-36 [19198598.001]
  • [Cites] Nat Cell Biol. 2009 Mar;11(3):344-9 [19219034.001]
  • [Cites] Lancet Neurol. 2009 Apr;8(4):334-44 [19278902.001]
  • [Cites] Cell. 2009 Apr 3;137(1):146-58 [19345193.001]
  • [Cites] J Biol Chem. 2009 May 8;284(19):12845-52 [19282288.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 5;106(18):7443-8 [19376973.001]
  • [Cites] J Biol Chem. 2009 May 22;284(21):14386-95 [19329794.001]
  • [Cites] Annu Rev Biochem. 2009;78:959-91 [19298183.001]
  • [Cites] Nat Struct Mol Biol. 2009 Jun;16(6):598-605 [19491937.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9033-8 [19451623.001]
  • [Cites] PLoS Genet. 2009 Jun;5(6):e1000517 [19521499.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):924-5 [19536253.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9679-84 [19487684.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Aug 14;386(1):257-62 [19523444.001]
  • [Cites] Folia Neuropathol. 2009;47(2):104-13 [19618334.001]
  • [Cites] Biochemistry. 2009 Aug 18;48(32):7732-45 [19580328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5 [19651612.001]
  • [Cites] FEBS Lett. 2009 Aug 20;583(16):2618-22 [19482025.001]
  • [Cites] Nat Struct Mol Biol. 2009 Sep;16(9):973-8 [19684598.001]
  • [Cites] Trends Genet. 2009 Sep;25(9):395-403 [19717203.001]
  • [Cites] Chem Biol. 2009 Sep 25;16(9):943-50 [19778722.001]
  • [Cites] Nature. 2009 Sep 24;461(7263):529-32 [19741608.001]
  • [Cites] FASEB J. 2009 Oct;23(10):3315-24 [19487308.001]
  • [Cites] Nat Chem Biol. 2009 Dec;5(12):936-46 [19915541.001]
  • [Cites] Cell Cycle. 2009 Dec;8(23):3960-70 [19901558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20051-6 [19892735.001]
  • [Cites] PLoS Pathog. 2009 Nov;5(11):e1000673 [19956709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20417-22 [19915150.001]
  • [Cites] Cell. 2009 Dec 11;139(6):1157-69 [20005808.001]
  • [Cites] J Biol Chem. 2009 Dec 18;284(51):35543-55 [19840945.001]
  • [Cites] PLoS One. 2009;4(12):e8221 [20011040.001]
  • [Cites] Neuron. 2009 Dec 24;64(6):783-90 [20064386.001]
  • [Cites] Nature. 2010 Jan 21;463(7279):353-5 [20090752.001]
  • [Cites] Genetics. 2010 Feb;184(2):393-400 [19917766.001]
  • [Cites] PLoS Pathog. 2010 Jan;6(1):e1000736 [20107515.001]
  • [Cites] Biochem Cell Biol. 2010 Feb;88(1):1-13 [20130674.001]
  • [Cites] Cell. 2010 Feb 5;140(3):421-35 [20144764.001]
  • [Cites] EMBO J. 2010 Feb 17;29(4):782-94 [20057357.001]
  • [Cites] Science. 2010 Feb 26;327(5969):1132-5 [20110469.001]
  • [Cites] Mol Cell. 2010 Feb 26;37(4):541-50 [20188672.001]
  • [Cites] Nat Methods. 2010 Mar;7(3):237-42 [20154676.001]
  • [Cites] Trends Cell Biol. 2010 Mar;20(3):125-33 [20071174.001]
  • [Cites] Dis Model Mech. 2010 Mar-Apr;3(3-4):194-208 [20038714.001]
  • [Cites] J Virol. 2010 Apr;84(7):3408-12 [20032192.001]
  • [Cites] J Cell Sci. 2010 Apr 15;123(Pt 8):1191-201 [20356930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6281-5 [20304795.001]
  • [Cites] Biochem J. 2010 May 15;428(1):95-101 [20196773.001]
  • [Cites] Biochemistry. 1996 Apr 30;35(17):5528-37 [8611544.001]
  • [Cites] Genetics. 1996 Dec;144(4):1375-86 [8978027.001]
  • [Cites] Cell. 1997 May 16;89(4):495-8 [9160741.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2045-7 [9197268.001]
  • [Cites] Cell. 1997 Aug 8;90(3):549-58 [9267034.001]
  • [Cites] Nature. 1997 Aug 28;388(6645):839-40 [9278044.001]
  • [Cites] Neurobiol Aging. 1997 Jul-Aug;18(4):351-7 [9330961.001]
  • [Cites] Genetics. 1997 Oct;147(2):507-19 [9335589.001]
  • [Cites] Annu Rev Microbiol. 1997;51:151-78 [9343347.001]
  • [Cites] Cell. 1998 May 1;93(3):301-3 [9590160.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73 [9600990.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jun;57(6):588-601 [9630238.001]
  • [Cites] Nat Med. 1998 Oct;4(10):1157-65 [9771749.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1318-20 [9809558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83 [9811807.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):11-4 [9934677.001]
  • [Cites] EMBO J. 1999 Apr 1;18(7):1974-81 [10202160.001]
  • [Cites] Chem Biol. 2004 Nov;11(11):1513-21 [15556002.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52319-23 [15448141.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):824-8 [15602547.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):315-20 [15630094.001]
  • [Cites] Science. 2005 Jan 14;307(5707):262-5 [15653506.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jan;4(1):71-8 [15688074.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7800-7 [15632170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400 [15705718.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):8808-12 [15618222.001]
  • [Cites] Anal Biochem. 2005 Apr 1;339(1):165-73 [15766724.001]
  • [Cites] Cell. 2005 Apr 22;121(2):195-206 [15851027.001]
  • [Cites] Nat Rev Genet. 2005 Jun;6(6):435-50 [15931169.001]
  • [Cites] Science. 2005 Jun 3;308(5727):1435-9 [15933194.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):765-72 [15944694.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):773-8 [15944695.001]
  • [Cites] NeuroRx. 2005 Jan;2(1):3-14 [15717053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10165-70 [16006506.001]
  • [Cites] Neurosci Lett. 2005 Nov 11;388(2):106-11 [16039063.001]
  • [Cites] EMBO J. 2005 Sep 7;24(17):3082-92 [16096644.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):262-5 [16148935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15477-82 [16223878.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):184-7 [15311209.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101(40):14326-32 [15388848.001]
  • [Cites] Science. 2004 Oct 29;306(5697):865-9 [15514157.001]
  • [Cites] Nature. 1967 May 20;214(5090):764-6 [4963878.001]
  • [Cites] Genetics. 1981 Aug;98(4):691-711 [7037537.001]
  • [Cites] Science. 1982 Apr 9;216(4542):136-44 [6801762.001]
  • [Cites] J Biol Chem. 1982 Jul 25;257(14):7936-9 [6806288.001]
  • [Cites] Science. 1982 Dec 24;218(4579):1309-11 [6815801.001]
  • [Cites] Cell. 1983 Dec;35(2 Pt 1):349-58 [6418385.001]
  • [Cites] Biochem Biophys Res Commun. 1984 May 16;120(3):885-90 [6375662.001]
  • [Cites] Cell. 1985 Apr;40(4):735-46 [2859120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9 [3159021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913-7 [3088567.001]
  • [Cites] J Gen Virol. 1987 Jan;68 ( Pt 1):79-89 [3100717.001]
  • [Cites] Science. 1991 Feb 8;251(4994):675-8 [1899488.001]
  • [Cites] Cell. 1993 Jul 2;73(7):1339-47 [8100741.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):393-7 [8401588.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10962-6 [7902575.001]
  • [Cites] Science. 1994 Apr 22;264(5158):566-9 [7909170.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2944-8 [7708753.001]
  • [Cites] Science. 1995 May 12;268(5212):880-4 [7754373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15871-6 [16247008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17342-7 [16293696.001]
  • [Cites] J Virol. 2006 Jan;80(2):1044-6 [16379006.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):133-46 [16473280.001]
  • [Cites] PLoS Biol. 2006 Jan;4(1):e6 [16300414.001]
  • [Cites] J Cell Sci. 1995 Apr;108 ( Pt 4):1617-27 [7615680.001]
  • [Cites] Nature. 1996 Jan 25;379(6563):339-43 [8552188.001]
  • [Cites] Biochemistry. 2006 May 16;45(19):6085-94 [16681381.001]
  • [Cites] Annu Rev Biochem. 2006;75:333-66 [16756495.001]
  • [Cites] Drug Metab Dispos. 2006 Jul;34(7):1136-44 [16581945.001]
  • [Cites] Science. 2006 Jul 7;313(5783):92-4 [16825570.001]
  • [Cites] Science. 2006 Jul 7;313(5783):94-7 [16825571.001]
  • [Cites] Mol Cell. 2006 Aug 4;23(3):425-38 [16885031.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):585-9 [16810177.001]
  • [Cites] Brain. 2006 Sep;129(Pt 9):2241-65 [16816391.001]
  • [Cites] N Engl J Med. 1999 Dec 16;341(25):1865-73 [10601505.001]
  • [Cites] Mol Cell. 2000 Jan;5(1):163-72 [10678178.001]
  • [Cites] Cell. 2000 Mar 31;101(1):57-66 [10778856.001]
  • [Cites] J Virol. 2000 May;74(10):4894-7 [10775631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4897-902 [10781096.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1317-21 [10958771.001]
  • [Cites] Nature. 2000 Sep 28;407(6803):477-83 [11028992.001]
  • [Cites] Neuroscience. 2000;100(4):677-80 [11036200.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):8916-22 [11073991.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Nov 29;355(1403):1669-76 [11127914.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):366-9 [11267875.001]
  • [Cites] Yeast. 2001 Apr;18(6):489-97 [11284005.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(6):1357-69 [11442834.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9836-41 [11504948.001]
  • [Cites] Nat Struct Biol. 2001 Nov;8(11):958-62 [11685242.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45160-7 [11574536.001]
  • [Cites] Science. 2002 Feb 1;295(5556):851-5 [11823641.001]
  • [Cites] Curr Biol. 2002 Apr 2;12(7):523-30 [11937020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5253-60 [11959975.001]
  • [Cites] Nat Struct Biol. 2002 May;9(5):389-96 [11938354.001]
  • [Cites] Nat Med. 2002 May;8(5):485-92 [11984593.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7402-7 [12032295.001]
  • [Cites] Neuron. 2002 Jun 13;34(6):921-32 [12086640.001]
  • [Cites] Ann Neurol. 2002 Oct;52(4):503-6 [12325081.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1185-6 [12411925.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16446-53 [12461168.001]
  • [Cites] Neurobiol Aging. 2003 Mar-Apr;24(2):197-211 [12498954.001]
  • [Cites] Science. 2003 Jan 31;299(5607):713-6 [12560553.001]
  • [Cites] Science. 2003 Apr 18;300(5618):486-9 [12702875.001]
  • [Cites] J Cell Biol. 2003 May 12;161(3):521-33 [12732614.001]
  • [Cites] J Virol. 2003 Aug;77(15):8462-9 [12857915.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9034-8 [12853572.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):549-52 [12891357.001]
  • [Cites] Evolution. 2003 Jul;57(7):1498-512 [12940355.001]
  • [Cites] Nat Biotechnol. 2003 Sep;21(9):1075-81 [12910243.001]
  • [Cites] J Virol. 2003 Oct;77(19):10288-94 [12970413.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):957-62 [14562059.001]
  • [Cites] Science. 2003 Oct 31;302(5646):871-4 [14593181.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49636-43 [14507919.001]
  • [Cites] J Theor Biol. 2004 Jan 21;226(2):205-14 [14643190.001]
  • [Cites] Cell. 2003 Dec 26;115(7):879-91 [14697205.001]
  • [Cites] Proc Biol Sci. 2003 Dec 22;270(1533):2573-8 [14728779.001]
  • [Cites] Ann Neurol. 2004 Feb;55(2):164-73 [14755719.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7378-83 [14668331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2287-92 [14983002.001]
  • [Cites] Biochemistry. 2004 Mar 16;43(10):2879-87 [15005623.001]
  • [Cites] Dement Geriatr Cogn Disord. 2004;17(3):158-63 [14739538.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):319-23 [15029195.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):323-8 [